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Abstract 
Jay Shankar Jha 
Department of Chemistry 
University of Kansas, July 24th, 2018 
Sulfur (S)-containing heterocyclic compounds possessing R1R2N–SO2R
3 functionality 
have been recognized as important due to their innate physical properties that affect biological 
systems marking them as attractive targets for probing biological pathways. Specifically, 
sulfonamides and sultams represent two significant compound classes, which exhibit broad 
ranges of biological activities. Similarly, natural products possessing the tetramic acid core 
structural motif have emerged as a rich chemotype due to their potent and broad biological 
activities. Several bioactive tetramic acid-containing compounds have been reported with a 
variety of activities, including antibacterial, anticancer and anti-inflammatory activities, as well 
as unique biological profiles in different cell assays. Tetramic acid analogs are also known to 
modulate protein-protein interactions.  
In light of the biological significance of the tetramic acid subunit, and the notable 
physical properties of sulfur containing compounds, we have become interested in the generation 
of S-analogs of tetramic acids in order to screen for biological activity, and to serve as new 
probes in Chemical Biology studies with our collaborators.  One such class is β-keto sultams, 
and their unsaturated analogs, both of which represent relatively unexplored chemical space.  
While there are several reports in the literature for the synthesis of tetramic acid-containing 
compounds, there are a relatively limited number of examples of the corresponding β-keto 
sultam analogs. Moreover, their unsaturated analogs are even more limited.  It is the purpose of 
this thesis to start our investigations to explore the substitution of the β-keto sultam group for the 
iv 
 
β-keto lactam subunit in drug-like tetramic acid-containing molecules, which ultimately has the 
potential to modulate biological activity as well as ADME profiles of the resulting analogs 
compounds. This thesis will describe the design and synthesis of β-keto sultam analogs of 
tetramic acids and their corresponding unsaturated and macrocyclic derivatives as novel 
electrophilic probes that can be modulated electronically, sterically, and stereochemically. 
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1.1 Introduction 
Sulfur (S)-containing heterocyclic compounds possessing R1R2N–SO2R
3 functionality 
have been recognized as important due to their innate physical properties that affect 
biological systems marking them as attractive targets for probing biological pathways. 
Specifically, sulfonamides and sultams represent two significant compound classes, which 
exhibit broad ranges of biological activities. Similarly, natural products possessing the 
tetramic acid core structural motif have emerged as a rich chemotype due to their potent and 
broad biological activities.1 Several bioactive tetramic acid-containing compounds, such as, 
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equisetin, integramycin, janolusimide etc. have been reported with a variety of activities, 
including antibacterial, anticancer and anti-inflammatory activities, as well as unique 
biological profiles in different cell assays.1 Tetramic acid analogs are also known to modulate 
protein-protein interactions.1d,e 
In light of the biological significance of the tetramic acid subunit, and the notable 
physical properties of sulfur-containing compounds such as enhanced Mulliken charge, 
ability of mild N-alkylation etc., we have become interested in the generation of S-analogs of 
tetramic acids in order to screen for biological activity, and to serve as new probes in 
Chemical Biology studies with our collaborators.  One such class is β-keto sultams, and their 
unsaturated analogs, both of which represent relatively unexplored chemical space.  While 
there are several reports in the literature for the synthesis of tetramic acid-containing 
compounds, there are a relatively limited number of examples of the corresponding β-keto 
sultam analogs. Moreover, their unsaturated analogs are even more limited.  It is the purpose 
of this thesis to start our investigations to explore the substitution of the β-keto sultam group 
for the β-keto lactam subunit in drug-like tetramic acid-containing molecules, which 
ultimately has the potential to modulate biological activity as well as ADME profiles of the 
resulting analogs compounds. 
This thesis will describe the design and synthesis of β-keto sultam analogs of tetramic 
acids and their corresponding unsaturated derivatives as novel electrophilic probes that can 
be modulated electronically, sterically, and stereochemically. A modular approach is 
described, whereby these compounds can be simply accessed from amino acids/esters and 
can be converted to the corresponding β-keto sultams by mesylation, N-sulfonylation and 
Dieckmann cyclization (Figure 1.1). Their unsaturated and macrocyclic counterparts can be 
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obtained by Knoevenagel condensation using several different aldehydes in short adaptable 
synthetic routes. Varying substituents and ring size, as well as adjusting electronic, steric and 
stereochemical parameters will modulate the properties of these compounds. These 
compounds represent excellent starting points in the development of specific molecular 
probes for identifying hotspots in reactive proteins and enzymes.2 Understanding the 
reactivity of such probes is a primary goal of this project, whereby compounds will be 
assessed against cysteine- and serine-based biological nucleophiles and whole proteome 
screening using activity-based protein profiling (ABPP).3 
 
Figure 1.1: Synthetic strategy of sultam analogs of tetramic acids. 
1.1.1 Sulfonamides and sultams: Properties and role in biological systems. 
Sulfonamides are one of the well-known functional groups in the field of 
pharmacology. Sulfonamides drugs are bacteriostatic and are one of the first drugs used for 
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chemotherapeutics and preventive care.4 This premise has inspired the proposed development 
of a number of modular methods within our laboratory for the construction of new 
electrophilic S-chemotypes with the aim of producing small libraries with attenuated thiol- 
and oxo-reactivity patterns, and improved selectivity.  Efforts directed towards the synthesis 
and applications of these S-heterocycles will exploit their unique chemical properties, which 
are many-fold as outlined in Figure 1.25 and include, (i) Mulliken charge enhancement at the 
heteroatom, (ii) tunable pKa, which affects differential rate and conditions for N-alkylation 
enabling modular synthesis, (iii) hard P=O/soft SO2 - engendering potential chemoselectivity 
with nucleophilic additions, (iv) variable oxidation states, (v) multivalency, (vi) Thorpe-
Ingold enhancement of cyclization rates, (vii) tunable electrophilicity to affect modulation 
within reactivity profiling and ABPP studies, (viii) the ability of sulfur nuclei to exist with 
stable tetrahedral geometry, thus presenting them as an ideal mimic of tetrahedral transition  
 
Figure 1.2: Salient features of sulfur 
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states involved in key biological processes, and (ix) the sp3 character of sultams relegates 
them to ‘non-flatland’ status in molecular architecture unlike their planar amide counterparts. 
Although sulfonamides are prevalent in drugs, their cyclic forms (sultams) are 
unnatural and less prevalent in the literature. Some of the synthesized sultam compounds are 
known to exhibit anti-proliferative and anti-HIV activities6a Others demonstrate inhibitory 
activity of trypsin-like serine protease factor XIa involved in blood coagulation,6b and 
modulator of lysosomal acidification involved in cellular function (Figure 1.3).6c 
 
Figure 1.3: Activity of sulfonamides and sultam compounds. 
The above discussion highlights the interesting properties of the R1R2N–SO2R
3 
moiety in both sulfonamides and sultams. The broad biological activity of sulfonamides and 
sultams is intriguing and has motivated our group to design and synthesize sultam 
compounds with unique properties using modular methods employing multi-functional 
N
H
NS
OO
iBu
H
N
O
OH
HO
NS
O
O
Me
OH
Me
N
Me
O
N
H
OO
N
NH
N
H
O iBu
O
S
HN
O
O
Cl
S
NH
O
O
O
N
H
O
N
O
O
N Me
OMe
S
N
iPr
Me
HN S
HN
NN
H
N
Br
O
O
N
N
S
OO
Me
Cl
CCR5 binding receptor
Inhibitor of lysosomal acidification Inhibitor of blood factor XIa
Inhibitor of necrosis factor 
for selective tumors
inhibitor of CKD 1/2 
and VGKF-RTKs
Hepatitis C virus protease inhibitor
7 
 
sulfonamide building blocks/linchpins for the synthesis of diverse array of sultams with 
variable ring size and functionality (Figure 1.4).  This body of work includes use of: vinyl 
sulfonamide linchpins in Michael addition and double aza-Michael addition reactions7, vinyl 
and allyl sulfonamides building blocks/linchpins in RCM reactions and RCM-Mitsunobu 
sequences.8, and vinyl sulfonamides, -halo aryl sulfonamides and -halo aryl aziridinyl 
sulfonamides in various complementary pairing (CP) and complimentary ambiphile pairing 
(CAP) strategies.9 In addition, the chemistry of mesylated amino esters was employed in 
Dieckmann cyclization strategies to generate novel amino acid derived -keto sultams as 
highlighted in Chapter 3 of Moon Young Hur’s thesis, and serves as the foundation for this 
dissertation.10 
  
Figure 1.4: Multi-Functional Sulfonamide Building Blocks. 
1.1.2 Tetramic acids: Natural products and their biological activities 
 Tetramic acids, formally 2,4-pyrrolidinediones, normally exist in equilibrium with 
their enol form. Tetramic acids have been known since the early 20th century, but gained 
prominence after the 1960s when they were found to be a key structural moiety in a variety 
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of natural products.11 Tetramic acid-containing compounds are often secondary metabolites 
isolated from a wide range of terrestrial and marine organisms such as fungi, cyanobacteria, 
bacteria, and sponges.12 They have attracted large interest in the field due to their broad range 
of bioactivities, including: antibiotic, antiviral, cytotoxicity, cell cycle inhibitory, and 
mycotoxicity.13  Some of the examples of prominent natural products containing tetramic 
acid as a core structural motif have been listed in Figure 1.5. The list contains: spirotetramat, 
a spirocyclic tetramic acid derivative and a lipid biosynthesis inhibitor, which has been 
postulated to block acetyl-coenzyme A carboxylase and has been used as a pesticide and 
insecticide.14 Streptosetin A is derived from marine actinomycetes and has been reported as a 
histone deacetylase (HDAC) inhibitor.15 Spiroscytalin is a fungus metabolite having 
phenylalanine-derived tetramic acid core, and was found to exhibit anti-proliferative activity 
against human tumor cell lines and is also known to have antimicrobial activities.16 
Reutericyclin is isolated from bacteria Lactobacillus reuteri, and has a 5-membered core, 
structurally related to the tetramic acid core. Reutericyclin is bactericidal to gram-positive 
bacteria and a broad range of food-related spoilage organisms and pathogens.17 Cryptocin, 
isolated from fungus, is a 3-acyl tetramic acid having a trans-decalin as a generic skeleton 
and is found to be antimycotic against Pyricularia oryzae, an agent that causes rice blast 
disease.18 Equisetin is an N-methyl serine-derived acyl tetramic acid produced by various 
Fusarium species fungi and possesses antibiotic and cytotoxic activity as well as inhibitory 
activity against mitochondrial ATPases and HIV-1 integrase in vitro.19 Integramycin is a 
hexacyclic tetramic acid-containing natural product that inhibits recombinant HIV-1 
integrase.20 Sch210972 is a decalin-containing tetramic acid derivative that inhibits cytokine 
receptor and is also a potential antiretroviral drug.21 JBIR-22 is reported as a proteasome 
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inhibitor,22 and inhibits protein-protein interaction by binding to the interface of the PAC3-
binding domain. Janolusimide is a lipophilic tripeptide, isolated from the nudibranch mollusk 
and is known to be a neurotoxin.23 Fusarisetin A, isolated form soil fungus, is a pentacyclic 
natural product consisting of a 5,5,5-angular tricycle motif, and is known to display 
inhibition of acinar morphogenesis along with cell migration and inhibition.24 
Diaporthichalasin, isolated form endophytic fungus, is a potent inhibitor of drug-
metabolizing enzyme CYP3A4.25 
 
Figure. 1.5: Natural products containing a tetramic acid as a core structural motif. 
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The above discussion highlights the tetramic acid core as an important structural 
motif in natural products that display diverse biological activities. Similarly, from the earlier 
discussion, it has been revealed that sulfonamides and sultams are an important class of 
compounds known to possess interesting biological properties. Collectively, the synergy in 
these two motifs has inspired studies aimed at the production of sultam analogs of tetramic 
acid that will incorporate diverse biological activities associated to tetramic acids, and 
compelling molecular features from the sultam moiety. 
In the course of designing and synthesizing several -keto sultams, we have focused 
on the synthesis of small molecule electrophilic probes, namely -keto vinyl sultams, as 
shown in Figure 1.6. These covalent probes possess doubly-activated Michael systems that 
are also present in a number of biologically active molecules and potential drug candidates 
such as bardoxolone methyl, cryptoquinone, and pyrrocidine A (Figure 1.6).26  
 
Figure 1.6: Bioactive compounds having doubly activated Michael acceptors. 
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Scifinder and PubChem database search of tetramic acids and their corresponding 
sultam analogs highlight that sultam analogs of tetramic acids are limited in the literature 
(Figure 1.7).27 Although the number of reports of incorporation of the -keto sultam moiety 
has increased over the last few years, collectively they are still limited when compared to 
their amide counterparts. Moreover, the reports of -keto vinyl sultams are still relatively 
void, which when coupled with their aforementioned potential as novel electrophilic probes, 
has inspired our work in this area. 
 
Figure 1.7: SciFinder and PubChem substructure searches carried out on the following 
dates (a) 7-16-2018 and (b) 4-7-2015 
1.1.3 Tetramic acids: Representative known synthetic methods  
Historically, several methods for the synthesis of the tetramic acid core have been 
reported, and have been extensively covered in two excellent reviews reported in 2008 and 
2010.28 Discussions of Dieckmann- and non-Dieckmann-derived tetramic acids, as well as 
derivatizations of the tetramic acid core, were covered in the dissertation of Moon Young 
Hur (PhD, 2015).10 Additional relatively recent work in the construction of the tetramic acid 
core is discussed further below.  
In 2010, Spatz and coworkers demonstrated the synthesis of the tetramic acid core 
using an Ugi–Dieckmann-reaction (Scheme 1.1).29 The authors used isocyano 
methylcarbonate 1.1.4 as a cleavable isocyanate for the Ugi 4-component-coupling reaction. 
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The Ugi reaction was performed by the condensation of amine 1.1.1 and aldehyde/ketone 
1.1.2 to generate an imine, which in due course reacted with acid 1.1.3 and isocyanate 1.1.4 
to furnish amide 1.1.5. Deprotonation of amide 1.1.5 with potassium t-butoxide initiates the 
Dieckmann-type cyclization of 1.1.6 by the enolized carboxylic acid to afford tetramic acid 
1.1.7a or 1.1.7b, along with the oxazolidinone leaving group 1.1.8. 
 
Scheme 1.1: Synthesis of tetramic acid core by Ugi–Dieckmaan condensation method. 
In 2010, Sarpong and Marcus synthesized the tetracyclic core of tetrapetalone A 
using a reductive alkylation of pyrrole (Scheme 1.2).30 En route to the synthesis, they 
constructed the tetramic acid core by alkylation of the ene-lactam moiety 1.2.1 using 
sequential treatment with LDA and MeI to yield 1.2.2. Conjugate addition of boron 
pinacolato ester to 1.2.2, followed by oxidation with sodium perborate, and Swern oxidation 
installed the tetramic acid moiety within 1.2.3. 
In 2010, Gu and Zakarian reported the synthesis of sintokamide A, and demonstrated 
the construction of the tetramic acid moiety (Scheme 1.3).31 En route to the synthesis of 
sintokamide A, the authors performed methyl ester hydrolysis of dipeptide 1.3.1 to furnish a 
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carboxylic acid, which was coupled with Meldrum’s acid using the Jouin procedure to 
generate 1.3.2.31 Intermediate 1.3.2 was next heated in the presence of MeCN, followed by 
addition of DEAD and PPh3 to afford the tetramic acid derivative 1.3.3. 
 
Scheme 1.2: Construction of the tetramic acid core during the synthesis of tetrapetalone A. 
 
Scheme 1.3: Construction of the tetramic acid core during the synthesis of sintokamide A. 
In 2012, Pettus and coworkers reported the synthesis of 3-methyl tetramic acid 1.4.3 
using a SmI2-promoted cyclization approach (Scheme 1.4).
32 The authors used amino acid 
ester 1.4.1 to generate amino acid derivative 1.4.2 by first protecting the amine with CbzCl 
and next reacting with 2-bromopropionyl bromide. Intermediate 1.4.2 was cyclized to 
tetramic acid 1.4.3 using SmI2, in the presence of HMPA, with subsequent exposure of the 
reaction mixture to diazomethane. This method was applicable to a wide range of amino 
acids such as valine, proline, leucine, phenylalanine and alanine. 
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Scheme 1.4: Construction of 3-methyl tetramic acid using SmI2. 
In 2013, Gao and coworkers demonstrated the cyclization of TBS-protected N-methyl 
amino alcohol 1.5.3 during the synthesis of Equisetin (Scheme 1.15).19d The authors started 
the synthesis using (+)-citronellal 1.5.1, and in several steps, converted it to alkene 1.5.2. 
Subsequent protection afforded TBS-protected alcohol 1.5.3 in nine linear steps. Dieckmann 
cyclization of 1.5.3 in the presence of sodium methoxide and MeOH constructed the tetramic 
acid core of equisetin 1.5.4. 
 
Scheme 1.5: Tetramic acid core construction during the synthesis of Equisetin. 
In 2014, Wang and coworkers demonstrated the synthesis of pyrrolidine-diones 
(Scheme 1.16).33 The authors coupled mono-ethyl malonate 1.6.1 and α-amino esters in the 
presence of EDC and DMAP to synthesize amide 1.6.2. Subsequent cyclization using sodium 
methoxide (Na/MeOH) in the presence of toluene furnished 3-methoxycarbonyl tetramic acid 
1.6.3. Finally, pyrrolidine-2,4-dione 1.6.4 was obtained by refluxing 1.6.3 in a mixture of 
acetonitrile and water. 
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Scheme 1.6: Synthesis of pyrrolidine-2,4-diones from mono-ethyl malonate. 
In 2014, Frontier and coworkers reported the total synthesis of tetrapetalone A-Me 
aglycon (Scheme 1.7).34 During their total synthesis, the authors subjected alcohol 1.7.1 to 
the Ley TPAP-oxidation conditions to furnish the corresponding aldehyde, which was 
subsequently cyclized to produce tetracycle 1.7.2 using an intramolecular Baylis-Hillman 
cyclization with Stryker’s reagent. Swern oxidation of 1.7.2 afforded the chlorinated tetramic 
acid tetracycle 1.7.3. 
 
Scheme 1.7: Construction of the tetramic acid core during the synthesis of tetrapetalone A. 
In 2015, Yamada and coworkers demonstrated the silver-catalyzed synthesis of 
several tetramic acid derivatives (Scheme 1.8).35 The authors used readily available and 
cheap propargylic amines 1.8.1 and carbon dioxide as starting materials. The reaction lead to 
the formation of oxazolidinone 1.8.2, which in the presence of DBU, underwent 
rearrangement to produce the corresponding tetramic acid 1.8.3.  
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Scheme 1.8: A one-pot synthesis of tetramic acids starting from propargyl amine. 
1.1.4 β-Keto sultams: Methods of synthesis  
Sulfur analogs of tetramic acids, termed -keto sultams, belong to an attractive 
chemotype class for probe and drug development due to the aforementioned bioisosteric 
equivalence of sulfonamides with corresponding amides.36  Over past few decades, a number 
of classical synthesis of -keto sultams has been reported, mostly using an intramolecular 
cyclization pathway, some representative synthetic strategies are discussed below.   
Stachel and Drasch, in 1976, described the synthesis of sultams using an 
intramolecular CSIC reaction involving esters as the electrophilic component (Scheme 1.9).37 
The authors synthesized several substituted sulfonates and sulfonamides 1.9.1 and prepared 
respective -keto sultone and sultams 1.9.2 in 30–60% yield using sodium methoxide as base 
in dry EtOH. Based on pKa analysis, it was revealed that most of the sultones and sultams 
existed in the enol form.   
 
Scheme 1.9: Synthesis of sultones and sultams involving ester electrophile. 
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In 1966, Snader and coworkers demonstrated the synthesis of benzofused sultams 
during the synthesis of Sulfostyril (Scheme 1.10a).38 The authors started their synthesis with 
sulfoacetic acid 1.10.1 and converted it to sulfoanilide 1.10.2 in three steps. Sulfoanilide was 
then hydrolyzed to acid and then cyclized to β-keto sultam 1.10.3 in the presence of 
polyphosphoric acid in excellent yield. 
In 1996, Tornus and Schaumann synthesized a six-membered β-keto sultam using a 
novel Diels-Alder reaction (Scheme 1.10b).39 The authors prepared the N-sulfonyl-alkyl-
amines 1.10.5 in situ using the corresponding sulfamoyl chlorides 1.10.4. A formal Diels-
Alder reaction between dienophile 1.10.5 and diene 1.10.6 generated β-keto sultam 1.10.7.  
 
Scheme 1.10: Synthesis of β-keto sultams 
Coppo and Fawzi in 1998, and Volovenko and coworkers in 2007, reported the 
synthesis of N-substituted benzofused β-keto sultams (Scheme 1.11).40 The authors began the 
synthesis with 2-aminobenzoic acid methyl ester 1.11.1, subsequent sulfonylation using 
methanesulfonyl chloride, followed by N-alkylation, generated aminobenzoates 1.11.2. 
Dieckmann ring closure of 1.11.2 was achieved using NaH in DMF to afford sultam 1.11.3 in 
good to excellent yield. 
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Scheme 1.11: Synthesis of N-substituted benzofused β-keto sultams. 
In 2012, Tabarrini and coworkers demonstrated the synthesis of a unique subclass of 
-keto sultams, namely, benzothiazine dioxide derivatives (Scheme 1.12).41 The authors 
commenced the synthesis with bromoacetate 1.12.1 and reacted it with sodium sulfite, 
followed by treatment with PCl5, to generate the corresponding sulfonyl chloride, which was 
subsequently treated with cyclopropyl amine to furnish sulfonamide 1.12.2. The sulfonamide 
1.12.2 was treated with substituted benzoyl chloride 1.12.3 to afford sultam intermediate 
1.12.4. The sultam intermediate was next converted to benzofused β-keto sultam 1.12.5 by N-
methylpiperazine installation, nitro group reduction, and ester hydrolysis. 
 
Scheme 1.12: Synthesis of benzothiazine dioxide derivatives. 
1.1.5 Vinyl sultams and β-keto vinyl sultams: Methods of synthesis 
There are several examples of the synthesis of vinyl sultams reported in the literature 
(Figure 1.8a) that will be outlined in the following pages.42 Reports of the corresponding  
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corresponding naturally occurring unsaturated tetramic acids of general structure 1.8.1 
(Figure 1.8b).43 Various acyclic vinyl sulfones, vinyl sulfonate, and vinyl sulfonamides 
(Figure 1.8c) have been reported as novel cysteine protease inhibitors44 In 1992, Hanzlik and 
Liu carried out thiol reactivity screening for known targets, and discovered that vinyl 
sulfones are inhibitors of cysteine proteases in papain and parasitic cruzain.44a In 2001 and 
2003, Roush44b–d reported that a series of vinyl sulfone, vinyl sulfonate and vinyl 
sulfonamide scaffolds were potent inhibitors of cruzain for the treatment of Chagas disease.  
 
Figure 1.8: -Keto vinyl sultams, vinyl tetramic acids and acyclic vinyl sulfones, vinyl 
sulfonamides and vinyl sulfonates.   
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falciparum. These examples qualify unsaturated sultams to be an important moiety in the 
field of drug discovery. Some of the examples for the synthesis of unsaturated sultams are 
discussed below.In 1999, Hanson and coworkers reported the synthesis of vinyl sultams 
employing an RCM strategy (Scheme 1.13).45 The authors synthesized vinyl sulfonamides 
1.13.2 by the reaction of amines with vinyl chlorides 1.13.1. The vinyl sulfonamides were 
next N-alkylated with 1-bromoalkene 1.13.3 to obtain diene 1.13.4, which underwent RCM 
to afford vinyl sultams 1.13.5 in excellent yields. The vinyl sultams 1.13.7 underwent 
stereoselective Diels-Alder reaction with cyclopentadiene in the presence of Lewis acid 
catalyst to obtain tricyclic sulfonamides 1.13.8 (Scheme 1.13b).46 
 
Scheme 1.13: Synthesis of a) vinyl sultams and b) tricyclic sulfonamides. 
In 2003, Hanessian and coworkers demonstrated the synthesis of functionally diverse 
bicyclic sulfonamides (Scheme 1.14). 47 The authors commenced the reaction by deprotecting 
Boc-protected propenyl proline benzyl ester 1.14.1, followed by the reaction with 
ethenesulfonyl chloride to afford the diene intermediate 1.14.2, which under RCM 
conditions, yielded bicyclic vinyl sultams 1.14.3 in moderate yield. 
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Scheme 1.14: Synthesis of bicyclic sultams via RCM 
In 2005, Metz and coworkers demonstrated the synthesis of sultams via use of an 
intramolecular Heck reaction (Scheme 1.15).48 The authors converted cyclic bromides 1.15.1 
to amines 1.15.2, which was next reacted with sulfonyl chloride 1.15.3 to afford the desired 
sulfonamides 1.15.4. Intramolecular Heck reaction on sulfonamides 1.15.4 yielded bicyclic 
exo-vinyl sultams 1.15.5 in good yield.  
 
Scheme 1.15: Synthesis of bicyclic exo-vinyl sultams via intramolecular Heck reaction. 
In 2008, Jimenez-Hopkins and Hanson reported a ring-closing metathesis (RCM) 
strategy for the synthesis of γ-hydroxy vinyl sultams (Scheme 1.16).49 The authors started the 
synthesis with amination of allylsulfonyl chloride 1.16.1 followed by Boc-protection to 
afford sulfonamide 1.16.2. Mitsunobu reaction on 1.16.2 with chiral, non-racemic alcohol 
1.16.3, obtained from corresponding glycidyl ether, furnished diene 1.16.4. The sulfonamide 
1.16.4 was cyclized using an RCM reaction and was next dihydroxylated, followed by 
conversion to the respective carbonate using phosgene. Final base-promoted elimination 
afforded the γ-hydroxy sultam 1.16.5. 
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Scheme 1.16: RCM strategy for the synthesis of γ-hydroxy vinyl sultams. 
In 2008, Zhou and Hanson developed intramolecular oxa-Michael and 
diastereoselective Baylis-Hillman reactions for the synthesis various sultam scaffolds 
(Scheme 1.17).50 The authors commenced the synthesis with amino alcohols 1.17.1, which 
were next TBS-protected, sulfonylated and N-alkylated to afford vinyl sulfonamides 1.17.2. 
The intramolecular oxa-Michael reaction was initiated by TBS-deprotection of 1.17.2 to 
afford medium-sized sultams 1.17.3 in good yields. Similarly, TBS-deprotection of 1.17.2 
using 10% HCl and conversion to the corresponding aldehyde via Dess–Martin oxidation, 
followed by Baylis-Hillman cyclization performed using DABCO, yielded a range of exo-
vinyl sultams 1.17.4. 
 
Scheme 1.17: Synthesis of sultam via oxa-Michael and Baylis-Hillman reactions. 
In 2016, Hanson and coworkers reported one-pot sequential protocols for the 
synthesis of several novel macrocycles bearing α,β-chemotypes (Scheme 1.18).42d The 
authors began the synthesis by coupling phosphate triene 1.18.1 with cross-metathesis 
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partner 1.18.2 using RCM/CM/chemoselective hydrogenation protocol to afford phosphate 
triester 1.18.3. Next, Pd-catalyzed, reductive allylic transposition and phosphate tether 
removal protocol provided 1,3-anti-diol 1.18.4. MOM protection and TBS deprotection of 
alcohols in 1.18.4 yielded carbinol 1.18.5. Mitsunobu reaction on 1.18.5 followed by 
reduction and sulfonylation afforded the sulfonamide 1.18.7. The desired macrocyclic  
α,β-unsaturated sultam 1.18.8 was obtained by RCM of diene 1.18.7 followed by MOM-
deprotection. 
 
Scheme 1.18: Synthesis of α,β-unsaturated sultam using one-pot sequential protocols. 
In 2017, Banerjee and coworkers reported the synthesis of fused vinyl sultams 
(Scheme 1.19).51 The fused vinyl sultams 1.19.3 were synthesized by the reaction of pyrrole-
2-carboxaldehydes 1.19.1 and arylmethanesulfonyl chloride 1.19.2 in the presence of sodium 
hydride in a one-pot tandem synthesis. 
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Scheme 1.19: One-pot tandem synthesis of fused vinyl sultams. 
In 2017, Nguyen and Retailleau reported the atom-economical synthesis of a variety 
of benzofused sultams (Scheme 1.20).52 The authors incorporated elemental sulfur into  
2-nitrochalcones 1.20.1 in the presence of 3-picoline to synthesize benzofused sultam 1.20.2.  
They were also able to derive the same product 1.20.2 using the β-hydroxy analogs of 
nitrochalcone 1.20.3 in a relatively lower yield. 
 
Scheme 1.20: Atom-economical synthesis of benzofused sultams. 
In 2017, Volovenko and coworkers reported the synthesis of sultam analogs of 
tetramic acid using amino esters (Scheme 1.21).53 The authors synthesized a series of 
tetramic acid sultam analogs using amino ester-containing cycloalkanes 1.21.1. The amine 
was mesylated and N-alkylated to afford 1.21.2. Sultam analog of tetramic acid 1.21.3 was 
obtained, when 1.21.2 was cyclized under sulfa-Dieckmann condition using KOtBu in DMF. 
The exo-vinyl sultam analog of tetramic acid 1.21.4 was obtained by treating 1.21.3 with 
DMF/DMA in MeOH under Knoevenagel conditions. 
N
H
X
CHO ArCH2SO2Cl
NaH, THF, 70 °C
12-14 h, 38-89%
+
N
X
S
Ar
O
O
X = CH, N
1.19.1
1.19.2
1.19.3
NO2
R
O
+ S
3-Picoline, 135 °C
N
R
O
S
O
O
H
16 h, 62-89%
NO2
R
OOH
3-Picoline, 135 °C
16 h, 56%
S +
R = alkyl, aryl R = p-FC6H4
1.20.1
1.20.2
1.20.3
25 
 
 
Scheme 1.21: Synthesis of unsaturated sultam analog of tetramic acid. 
1.2 Results 
Intrigued by the potent bioactivities of tetramic acid-containing natural products, 
sulfonamides and sultams, we began the design and synthesis of β-keto sultam analogs of 
tetramic acids. The key modification in the tetramic acid moiety is the replacement of the 
amide group (-NH-CO-) with a sulfonamide group (-NH-SO2-).  The synthesis of sultams has 
been reviewed in 2011, 2013 and recently in 2018.54  Our lab has a long history in the 
development of several different methods for the facile synthesis of diverse S-heterocycles 
and sultam compounds.55 Among these, highlights include, (i) a number of transition metal-
catalyzed approaches using RCM, (ii) “click-click-cyclize”, (iii) complementary pairing (CP) 
and complementary ambiphile pairing (CAP) strategies, and (iv) reagent-based diversity-
oriented synthesis (DOS). The click-click-cyclize strategy has been explored for the synthesis 
of skeletally diverse sultams via functional group pairing between vinyl sulfonamides 
linchpins and an array of functional groups.  
In 2015, Moon Young reported new syntheses of β-keto sultam analogs of tetramic 
acid involving acyclic and cyclic amino esters (PhD Thesis, 2015), as well derivatization 
chemistry.10 This thesis aims to extend on the body of work on -keto sultams and targets 
unsaturated sultam analogs, namely -keto vinyl sultams, which can be modulated 
electronically, sterically and stereochemically. These unique S-containing electrophiles will 
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be assessed as molecular probes in order to assist in targeting rare protein residues and 
shallow binding sites to alleviate or eliminate drug resistance, mutation, and toxicity.56 
Reactivity profiling studies using 19F–NMR are being conducted to monitor the rate at which 
the unsaturated sultams react with cysteine residue and hence give an idea of ranking them 
with several other known electrophilic probes, which will test our above mentioned 
hypothesis on the unsaturated sultams. Our ultimate goal is to use these chemotypes in 
activity–based protein profiling (ABPP) studies. 
Previously, we have reported the synthesis of unsaturated sultam analogs of tetramic 
acids using a strategy we term ‘click-click-cyclize’.55e This concept, a variant of build-
couple-pair (BCP)57 utilizes two simple click reactions as defined by Sharpless58 namely  
N-sulfonylation and N-alkylation, followed by a cyclization event, to construct core sultam 
subunits.  In this thesis, a variety of β-keto vinyl sultam analogs of tetramic acids have been 
targeted using a modular method employing (i) simple N-mesylation, followed by  
(ii) N-sulfonamide alkylation under mild conditions, (iii) Dieckmann-type cyclization and a 
(iv) simple Knoevenagel condensation reaction with a range of aldehydes (Figure 1.9).  
Chapter 2 aims to embed the β-keto vinyl sultam moiety in a macrocyclic framework. 
 
Figure 1.9: Synthetic strategy for the synthesis of unsaturated sultams 
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1.2.1 Synthetic design of -keto vinyl sultam analogs of tetramic acids 
As highlighted in Figure 1.10, we are implementing a simple ‘click–click–cyclize’ 
strategy utilizing amino acids, methane sulfonyl chloride and benzyl bromides that will be 
attenuated electronically, sterically, and stereochemically. Attention to the enol-keto 
tautomerization equilibrium will also be sought with the employment of functionality and 
ring size expansion. The targeted sultam analogs of tetramic acids can be readily converted to 
structurally diverse -keto vinyl sultam analogs (1.10-A, 1.10-D) by reacting with an array of 
aldehydes, carboxylic acids while enolic-type unsaturated sultams (1.10-B, 1.10-C) can be 
obtained by reacting with alkylisocynate and alkyl halides. 
 
Figure 1.10: Synthetic design for unsaturated sultams. 
1.2.2 Synthesis of -keto vinyl sultam analogs of tetramic acids 
We started this project using an array of amino acids, namely, valine, leucine, 
isoleucine, phenylalanine and 4-nitro phenylalanine. This thesis chapter is specific to 
phenylalanine and 4-nitro phenylalanine. Thus, amino acid 1.22.1 was esterified using 
thionyl chloride in the presence of MeOH at 60 ˚C (Scheme 1.22). After 6 h, MeOH was 
removed via reduced pressure evaporation and the reaction mixture was dissolved in dry 
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CH2Cl2. The crude reaction mixture was subjected to mesylation using MsCl/Et3N, to 
generate the mesylated amino ester 1.22.3. The reaction was completed in 6 to 8 hours with 
excellent yields of 85–90% over two steps.  Subsequent benzylation furnished N-benzylated 
amino ester 1.22.4. To carry out this reaction, the amino ester was dissolved in dry 
acetonitrile and was refluxed with benzyl bromide in the presence of K2CO3. The acyclic 
intermediate 1.22.4 was then cyclized under Dieckmann-like condition to afford the -keto 
sultam 1.22.5. This crucial cyclization was optimized using LiHMDS in dry THF at low 
temperature. Several runs demonstrated that dry solvent was a very important requirement 
for this reaction, as the presence of moisture in the reaction mixture resulted in no reaction, 
leaving behind unreacted starting material. 
 
Scheme 1.22: Synthesis of -keto sultam analogs of tetramic acids. 
Tetramic acids can exhibit keto-enol tautomerization. There are several literature 
examples indicating the keto-form as the predominant tautomer in a tetramic acid.59 
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However, in 1984, Rooney and coworkers reported the predominance of the enol-form in 
diketo-sultam 1.11-A (Figure 1.12a), which was verified by 13C NMR in Me2CO-d6 and 
solid-state IR studies.60 Stachel and Drasch reported predominance of the enol-form in 
sultams 1.11-B (Figure 1.12b), which was verified by both pKa and IR studies.61 In 2009, 
Jeong and Moloney reported the tautomeric behavior of the tetramic acid 1.11-C in solution 
along with computational calculations, and mentioned the characteristic 13C NMR chemical 
shift for both the keto and enol-forms of tetramic acid 1.11-C (Figure 1.12C).62  
We have observed the methylene protons at the C5 position (Figure 1.12d) in the  
1H NMR spectra in CDCl3 for the β-keto sultam analogs 1.11-D. In the NMR of 1.11-D, the 
13C carbon resonance at C5 appears between 195.1–206.1 ppm and also lacks the expected 
sp2-CH resonance at 170–175 ppm for the enol tautomer. The keto-form is further verified by  
 
Figure 1.11. Keto-enol tautomerism of in tetramic acid and β-keto-sultam analogs of 
tetramic acids a) and b) literature precedence c) characteristics 13C-NMR chemical shift for 
tetramic acid d) our observation of 13C-NMR chemical shift on β-keto sultam analogs of 
tetramic acids. 
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the carbonyl absorption (1748-1767 cm-1) in the IR spectrum without any detection of the 
hydroxyl absorption. However, when MeOH-d4 was used as the NMR solvent we also 
observed an additional 13C carbon resonance for C5 at 166.7 ppm for the β-keto sultam 1.12-
E, suggesting the enol tautomer. From 1H NMR analysis, the enol-tautomer in MeOH-d4 was 
found to be ~ 21–25%. Additionally, two peaks at -64.00 and -64.05 ppm in the 19F NMR 
spectrum in MeOH-d4 provides additional evidence for the enol-keto tautomerization in 
MeOH. 
1.2.3 Knoevenagel condensation to unsaturated tetramic acids 
With the β-keto sultam analogs in hand, efforts focused on the generation of  
-keto vinyl sultam analogs, utilizing literature precedent employing Knoevenagel 
condensations with a set of aromatic aldehydes.  The Knoevenagel condensation,63 described 
by Emil Knoevenagel, is a classic organic synthesis reaction in which an active hydrogen 
compound (nucleophile) undergoes nucleophilic addition with an aldehyde or ketone in the 
presence of a basic catalyst, to form a C–C bond (Figure 1.12). The reaction normally 
undergoes spontaneous dehydration to generate an unsaturated product. 
 
Figure 1.12: General scheme of Knoevenagel condensation. 
Some notable examples of the Knoevenagel condensation carried on tetramic acids 
related to our work are mentioned below.  In 2002, Saudi and coworkers demonstrated a 
Knoevenagel condensation on tetramic acid 1.23.1 (Scheme 1.23).64 The authors used the 
reaction of 1,5-diphenylpyrrolidine-2,4-dione 1.23.1 with several carbonyl compounds, 
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whereby they reported the Knoevenagel condensation with a range of carbonyl compounds in 
acidic medium to afford unsaturated tetramic acid 1.23.5. 1.23.1 when reacted with isatin 
1.23.2 in acidic medium, a Knoevenagel condensation product 1.23.3 was formed. The same 
reaction in alkaline medium produced the 4-quinoline carboxylic acid derivative 1.23.4.  In 
contrast, amines react with 1.23.1 to yield 4-substituted amino pyrroline-2-ones 1.23.6. 
 
Scheme 1.23: Reactions of tetramic acid with carbonyl compounds and amines. 
In 2011, Beyer and coworkers reported the asymmetric total synthesis of the indole 
alkaloid cyclopiazonic acid (Scheme 1.24).65 En route towards their synthesis, the authors 
prepared chiral indole-ester derivative 1.24.1, which underwent cationic cyclization in the 
presence of triflic acid to form the 5-membered ring of pyrrolidine 1.24.2 simultaneously in a 
1:1 diastereomeric ratio. The next synthetic step was a mercaptomethanol-mediated 
denosylation and construction of the tetramic acid core using acetyl-Meldrum’s acid (AMA), 
to afford the N-protected cyclopiazonic acid 1.24.3 in an overall one-pot process. 
In 2014, Sengoku and coworkers demonstrated that phenylalanine-derived tetramic 
acid 1.25.1, when treated with acetone or sterically hindered 9-anthraldehyde, leads to the 
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formation of corresponding ene-dione 1.25.2 in excellent yield (Scheme 1.25).66 The authors 
demonstrated that such a reaction was only possible with ketones and hindered aldehydes in 
the presence of L-proline as catalyst. Unhindered aldehydes produced the dimerized product 
1.25.3. Use of base catalysts such as piperidine, pyrrolidine, L-serine, L-lysine and L-aspartic 
acid also failed to produce the desired Knoevenagel condensation product. 
 
Scheme 1.24: Asymmetric synthesis of cyclopiazonic acid  
 
Scheme 1.25: Knoevenagel condensation between tetramic acid and carbonyl compounds.  
In 2012, Sengoku and coworkers demonstrated the synthesis of tetramic acids 1.26.2 
using condensation-decarboxylation reactions starting from N-protected amino acids 1.26.1 
(Scheme 1.26).67 The tetramic acids 1.26.2 were then condensed with a carboxylic acid in the 
presence of EDCI and DMAP to provide 4-O-acetyltetramic acid 1.26.3, which underwent 
1,3-acyl transfer to afford the 3-acyl tetramic acid 1.26.4. In this work, the authors used a 
rearrangement reaction rather than a Knoevenagel condensation reaction to synthesize 3-acyl 
tetramic acids.  Similarly, in 2005, Piric and coworkers reported the synthesis of tetramic 
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acid 1.26.2. The authors further reacted 1.26.2 with DMF/DMA in the presence of CH2Cl2 to 
synthesize unsaturated tetramic acid 1.26.5 employing the Knoevenagel condensation 
(Scheme 1.26).68 
In 2017, Volovenko and coworkers reported use of a Knoevenagel condensation of  
the -keto sultam analog of the tetramic acid previously described in Scheme 1.21.53 The 
authors synthesized -keto vinyl sultams 1.13-A from -keto sultams 1.13-B using 
DMF/DMA in MeOH under Knoevenagel condition (Figure 1.13a). 
 
Scheme 1.26: Synthesis of 3-substituted tetramic acid. 
The above discussion reveals that the common method for Knoevenagel condensation 
is the use of bases such as proline, piperidine, Et3N, in polar protic solvents such as EtOH. 
Unfortunately, most of the sultam analogs of tetramic acid failed to deliver the desired 
condensation product under these conditions. The only reaction that was successful using 
these conditions was between the valine-derived -keto sultam with piperonal, yielding 56% 
of the desired product (Figure 1.13b). Regrettably, we were not able to reproduce similar 
types of result with other amino acid-derived -keto sultams and various aldehydes. 
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Figure 1.13: Knoevenagel condensation with -keto sultam 
In studies attempting to find suitable conditions for the Knoevenagel condensation 
that will be applicable for a wide range of tetramic acid analogs and aldehydes, we screened 
several bases, catalysts, solvents and temperature conditions. The list of several conditions is 
mentioned in Table 1. Several bases were tested, including proline, piperidine, Et3N, 
diisopropylethyl amine (Hunig’s base), and DBU. In addition, the Lewis acids InCl3 and 
TiCl4 were also screened for the reaction. Two different temperature conditions i.e. room 
temperature and 50 ˚C were maintained for the reaction. Polar solvents like THF, EtOH, and 
CH3CN were considered for the reaction. None of the above-mentioned reagents, solvents 
and catalyst was helpful for the desired product formation. After initial failure of the 
condensation step, a more thorough literature search revealed the use of trifluoroethanol 
(TFE) by several laboratories as the solvent of choice in a range of condensation and 
multicomponent reactions.69 We felt that TFE being a polar solvent with high ionizing 
capability and low nucleophilicity, should be an effective solvent for our condensation 
reaction condition. Gratifyingly, use of TFE in the presence of L-proline as catalyst at 50 ˚C, 
we were able to condense the sultam analog of tetramic acid 1.22.5 with several aromatic 
aldehydes (R3CHO) such as benzaldehyde, 4-fluoro benzaldehyde, p-anisaldehyde, 
piperonal, and 4-fluorocinnamaldehyde to afford the desired -keto vinyl sultams of general 
structure 1.27.1 (Scheme 1.27). Following this protocol, a small library of 1.27.1 analogs has 
been synthesized, and summarized in Table 2. 
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Table 1: Conditions for Knoevenagel condensation 
SN Base Catalyst Temp. (˚C) Solvent Observation 
1 -  Proline 50 EtOH 
Decomposition of starting 
material  
2 -  Piperidine 50 EtOH 
Decomposition of starting 
material  
3  - Piperidine 50 THF 
Decomposition of starting 
material  
4  - Piperidine RT THF 
Decomposition of starting 
material  
5  - Piperidine RT MeCN 
Decomposition of starting 
material  
6 TEA -  Microwave MeCN 
Decomposition of starting 
material  
7 TEA NaI/TMSOTfa RT  MeCN 
Decomposition of starting 
material  
8 -  InCl3/Ac2O
a RT  THF 
Decomposition of starting 
material  
9 TEA TiCl4 -78 THF 
Decomposition of starting 
material  
10 DIPEA TiCl4 -78 THF 
Decomposition of starting 
material  
11 DBU TiCl4 -78 THF 
Decomposition of starting 
material  
12  - Proline  50 CF3CH2OH Reaction occurred  
a = used in stoichiometric amount as a reagent. 
 
Scheme 1.27: Synthesis of -keto-vinyl sultam analog of tetramic acid. 
An analysis of the Knoevenagel condensation products reveals that electron donating groups 
on the aldehyde component enhances the yield of the product (reaction involving aldehyde 
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A), whereas electron withdrawing effect (reaction involving aldehyde B), decreases the yield. 
Introduction of substituents to the aldehyde had little effect in the overall yield of the product 
(reaction involving aldehyde C). 
In the course of this work, efforts to generate macrocyclic isomers through an RCM approach 
revealed that our originally desired target possessing an E-configured olefin geometry, which 
we sought in the Knoevenagel strategy, actually produced the Z-configured olefin, as 
revealed by X-ray crystal structure (Figure 1.14). 
Table 2: -Keto vinyl sultam of tetramic acids. 
Entry R1 R2 R3CHO Yield (%) Entry R1 R2 R3CHO Yield (%) 
1 H H A 54  10 NO2 H B 45  
2 H F A 50  11 NO2 F C 58  
3 H Cl A 49  12 NO2 Cl C 52  
4 NO2 H A 57  13 H Cl C 44  
5 NO2 F A 57  14 H F C 41  
6 NO2 Cl B 40  15 NO2 Cl C 51  
7 H H B 47  16 NO2 H D 51  
8 H F B 28  17 NO2 F D 55  
9 H Cl B 43  18 H Cl E 42  
 
In order to further assess this result, we compared the 1H NMR chemical shift of the 
vinyl proton within β-keto vinyl sultams analogs 1.15-A, B and C, and the literature reported 
spirocyclic vinyl sultam 1.15-D (Figure 1.15). The chemical shift for the vinylic proton of all 
three β-keto vinyl sultams analogs 1.15-A, and B fall in the range of 7.72–7.85 ppm and all 
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Figure 1.14: X-ray structure of the exo-vinyl sultam analog of tetramic acid.  
 
Figure 1.15: Chemical shift of vinylic protons of -keto vinyl sultams. 
appear as a singlet. The β-keto vinyl sultams 1.15-C (possessing styrene substitution) has 
doublet splitting for the vinylic proton with a coupling constant of 12.0 Hz. Volovenkoa and 
coworkers synthesized the spirocyclic β-keto vinyl sultam 1.15–D and reported the chemical 
shift of the vinylic proton to be in the7.60–7.62 ppm.53 Collectively, the chemical shifts of 
the vinylic protons provide additional evidence for the Z-configured isomers of the β-keto 
vinyl sultam analogs 1.15- A, B and C. 
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Although, we succeeded in the Knoevenagel condensation of aromatic aldehydes with 
the amino acid-derived -keto sultams, the yields are moderate, ranging from 28–56%. We 
still seek more optimized conditions using TFE as a solvent. Also, suitable conditions for the 
condensation of aliphatic aldehydes should be analyzed as we were unable to link aliphatic 
aldehydes to tetramic acid analogs. 
1.2.4 Reactivity profiling of β-keto vinyl sultams using fluorine NMR. 
With the β-keto vinyl sultam analogs in hand, we have begun initial investigations 
involving reactivity profiling with thiols and cysteine residues to establish reactivity patterns 
in order to provide emperical data for their concurrent use as electrophilic probes in activity-
based protein profiling (ABPP) investigations in the laboratories of our collaborators.  ABPP 
is a technology to broadly assess reactive protein functionality and aid in the identification 
and mapping of ligandable hotspots in whole proteomes and allow pharmacological 
interrogation of difficult targets.70 
Recently, chemical biology ABPP studies have been augmented by a number of thiol 
reactivity studies in order to identify and rank reactivity trends among chemotypes, and are a 
“natural fit” for prescreening electrophilic covalent modifiers (CMs) for ABPP studies 
(Figure 1.16). In 2003, Roush and coworkers44a-d carried out thiol reactivity studies related to 
the inhibition of cysteine proteases papain and parasitic cruzain using vinyl sulfones, 
sulfonates, sulfonamides and their derivatives of general structure 1.16a.  This study was 
further substantiated by Rosenthal in 2006-using exo-vinyl sultams 1.16-b,44e Love in 2016-
using arylvinyl sulfones 1.16-c and alkynamides 1.16-d,71 and Bogyo in 2016-using peptidic 
vinylsulfones 1.16-e.44f Studies involving hetero-Michael additions into ,-unsaturated 
carbonyl systems were recently detailed in a 2017 perspective co-authored by Brummond  
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Figure 1.16: Electrophilic covalent modifiers for ABPP studies.  
and Harki,72 including -methylene cyclopentanones 1.16-f,73 -methylene--lactone 1.16-
g74 and vinyl lactones 1.16-h.75 This detailed perspective sheds light on extensive biological 
activities of a number of natural products and drugs bearing ,-unsaturated carbonyls, and 
details studies quantifying thiol reactivity patterns using various kinetic techniques. 
Overarching systematic investigations comparing thiol-electrophile reactivity patterns across 
compound classes, however, have only recently begun to emerge.A seminal paper in 2014 by 
Flanagan and co-scientists at Pfizer76 characterized and reported glutathione (GSH) reactivity 
with simple electrophilic warheads, and elevated the concept of reactivity-based thiol 
screening assays for chemotypes. In this study, thiol/nucleophilic/GSH reactivity data was 
reported on a number of simple acrylamides 1.16-i, alkynamides 1.16-j, and their 
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sulfonamide/sultam derivatives 1.16-k, which were elegantly detailed.  Augmenting this 
work were (i) a 2015 systematic study by Cee and co-scientists at Amgen detailing GSH 
reactivity patterns within a set of aryl substituted N-arylacrylamides 1.16-l,77 (ii) the novel 
strain release studies using substituted arylbicyclo[1.1.0]butylsulfones 1.16-m as 
chemoselective Cys-reactive probes reported by Baran/Pfizer in 2017 in a joint academic-
industrial collaboration,78 and (iii) a 2017 study by Palkowitz and co-scientists at Eli Lilly 
reporting the enhanced thiol reactivity patterns of a diverse set of  
N-acryloyl azetidines 1.16-n.79  Collectively, these studies have yielded notable data, 
whereby small acyclic fragment-based modifiers are in the majority.  
For these initial reactivity studies, we have employed 19F–NMR as an analytical tool. 
19F–NMR studies is a well established method for the elucidation of protein folding, protein 
dynamics, enzyme kinetics, and ligand interaction both in vivo and in vitro.80 Although 19F 
NMR has been extensively reported to monitor protein dynamics, vide infra, and has been 
termed by Pomerantz as a bioorthogonal method,81 its use to monitor reactions is much less 
prevalent.82,83  Use of 19F to monitor reactions, while less prevalent, has been reported by 
Berkowitz.84 
Following our goal of synthesizing electrophilic probes and their potenital use as 
inhibitors in ABPP studies, we carried out initial reactivity profiling experiments by reacting 
the β-keto vinyl sultam 1.17-A with N-acetylcysteine methyl ester 1.17-B (Figure 1.17). The 
reactions were carried out in an NMR tube and the rate of decrease in the intensity of fluorine 
peak of starting material was monitored and plotted against time in order to measure the rate 
of the reaction. 
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Figure 1.17: 19F-NMR studies of -keto vinyl sultam 
To perform the aforementioned reaction, 25 mM stock solution of 1.17-A was 
prepared in CH3CN. Similarly, 125 mM stock solutions each of Et3N, N-acetylcysteine 
methyl ester and internal standard (Trifluorotoluene or trichlorofluoromethane was used as 
internal standard) were also prepared in CH3CN. 100 µL each of 1.17-A, internal standard, 
and nucleophile were added, followed by the addition of the required amount of CH3CN to 
maintain the concentration of reaction at 5 mM.  Finally, Et3N was added to the NMR tube 
and was immediately subjected to obtain 19F-NMR spectrum. 19F-NMR intensities at 
different time intervals were noted to obtain a concentration vs time plot along with % 
conversion graph. 
The log of concentration vs time plot revealed a linear dependence between time and 
log of concentration of starting material when subjected to pseudo-first order conditions. The 
pseudo-first order condition was maintained by adding excess of nucleophile and base  
(5 equiv. each) compared with 1.17-A. A representative plot of pseudo-first order conditions 
for the reaction of 1.27.3 with N-acetylcysteine methyl ester is shown in Figure 1.18.  
The % conversion graph for the Michael addition reaction performed in NMR tube is 
shown in Figure 1.19 as reported by Baran and coworkers.78 The difference in reactivity of 
some of the β-keto vinyl sultams (1.27.2–1.27.5) can be rationalized from their distinct 
electrophilic nature. Nucleophilic attack by N-acetylcysteine methyl ester is less pronounced 
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at the electrophilic site of 1.27.5 due to the electron-donating nature of the methoxy 
substituent that decreases the Michael accepting electrophilicity via resonance. In the case of 
1.27.2, which lacks an electron- donating group, a faster nucleophilic reaction is seen. The % 
conversion graph shown in Figure 1.19 also implies that the substituent at the olefin of the β-
keto vinyl sultam governs the relative reactivity of the nucleophile to Michael addition. 
While the amino acid side chain, as well as the N-substituent, has no effect in these simple 
addition reactions, their affect using more elaborate cysteine-containing small peptides in in 
vitro reactivity profiling studies, as well as in ABPP experiments, awaits to be seen. 
  
Figure 1.18: Pseudo-first order reaction of -keto vinyl sultam analog 1.27.3 with N-acetyl 
cysteine methyl ester. 
Notably, the reaction between β-keto vinyl sultam analogs and N-acetylcysteine 
methyl ester resulted in the appearance of two fluorine peaks in the 19F–NMR spectrum, that 
appear in equal intensity, which are tentatively assigned as two of four possible 
diastereomeric addition products.  In the case of the reaction with 1.27.3, four fluorine peaks 
were seen suggesting all four possible diastereomeric products were seen. 
O2N
S
N
O
O
O
OMe
F
1.27.3
43 
 
 
 
Figure 1.19: Percentage conversion vs time graph for reaction between β-keto vinyl sultams 
with N-acetyl cysteine methyl ester. 
1.3 Future work 
 We have reported synthetic studies and initial reactivity profiling of -keto vinyl 
sultam analogs of tetramic acids.  With these results in hand, we are providing a list of work 
to be carried out by subsequent researchers in the group on this project, which includes:  
(i)  Detailed studies on reactivity profiling with several different thiols and cysteine 
containing peptides are forthcoming and will be conducted to rank the reactivity of 
each -keto vinyl sultam. 
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(ii)  Complete characterization of the thiol addition products obtained by the reaction 
between -keto vinyl sultams and several different thiols will be conducted to 
confirm the identity of the products. 
(iii)  The yield of -keto vinyl sultams during the Knoevenagel condensation was 
moderate, further optimization of the reaction will be done to enhance the yield of the 
reaction.  
(iv)  We were not able to obtain -keto vinyl sultams when aliphatic aldehydes were used 
in the Knoevenagel condensation. Effort will be made to synthesize -keto vinyl 
sultams using aliphatic aldehydes.  
1.4 Conclusion 
An efficient method for the synthesis of a small library of β-keto vinyl sultams, 
analogs of tetramic acids, has been reported. This method is applicable to a variety of 
aromatic aldehydes and sultam analogs of tetramic acids derived from several amino acids. 
Initial reactivity profiling results of a small set of these β-keto vinyl sultams, varying in 
olefinic substituents, using N–acetylcysteine methyl ester as the nucleophile, and monitoring 
with 19F–NMR has been reported.  Using a simple percent conversion versus time metric, 
appreciable differences in reactivity between these β-keto vinyl sultam analogs is seen, and 
indicates that the substituent at the olefin of the β-keto vinyl sultam governs the relative 
reactivity of the N-acetylcysteine methyl ester nucleophile. Data reported herein, warrants 
further reactivity profiling studies, including use of small peptides in aqueous solvent, as well 
as in collaborative ABPP studies in whole proteomes. 
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Chapter: 2 
Synthetic Approach towards Macrocyclic β-Keto Vinyl Sultams: 
Novel Macrocidin-like Tetramic Acid Analogs 
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2.1 Introduction 
The design and development of efficient and economical protocols for the synthesis 
of medium- and large-sized bioactive heterocycles is an important component of the 
screening campaign for facilitating drug discovery. In particular, macrocyclic tetramic acid-
containing natural products demonstrate a wide range of bioactivities and hence construction 
of macrocycles with the tetramic acid core is synthetically noteworthy. Macrocycles 
containing sulfur analogs of tetramic acids are also of great interest as they may lead to a new 
sub-class of heterocyclic molecules.  
Macrocyclic tetramic acid-containing compounds are also prevalent in the literature; 
however, their macrocyclic -keto sultam counterparts are void.  As noted in Chapter 1, 
sulfur (S)-based heterocycles possessing the R1R2N–SO2R
3 functional group have been 
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recognized as important due to their intrinsic physical properties capable of influencing 
biological systems.   
Macrocyclic sultams are beginning to emerge in the literature1 as seen in Figure 2.1 
[2.1-A–D], however, to the best of our knowledge, reports of macrocyclic -keto and -keto 
vinyl sultam analogs are void in the literature. This portion of the thesis will describe the 
design and attempted routes toward the synthesis of macrocyclic -keto vinyl sultam analogs 
of tetramic acids (Figure 2.1), that can be modulated electronically, sterically, and 
stereochemically. 
 
Figure 2.1: Synthetic strategy of macrocyclic β-keto sultam analogs of tetramic acids. 
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2.1.1 Macrocyclic tetramic acids: Natural products and biological activities 
Macrocyclic compounds have an immense importance in applied chemistry. They 
have attracted a huge interest in research and development in the field of organic synthesis. 
Macrocycles can display remarkable features, such as selectivity, flexibility, conformational 
pre-organization, and high affinity with protein targets and hence are promising molecules 
for the modulation of protein-protein interactions.2 Both natural and synthetic macrocyclic 
analogs display a wide range of biological activities ranging from anti-fungal, anti-
helminthic, antibiotics, anti-viral and insecticidal agents in agriculture.3 Macrocyclic organic 
compounds also demonstrate inhibitory effects, such as CDK2/cyclin A, Hsp90 and protein 
kinase C inhibitions in drug discovery.4 Additionally, the significance of macrocycles has 
been demonstrated in drug development with more than a hundred naturally occurring and 
synthetic macrocycle-containing compounds currently being explored in therapy.5  
Compared to small-molecules, macrocyclic compounds can address challenging and 
biologically compelling targets, such as protein-protein interface in a more efficient way.6 
Macrocycles have both pharmacological and physiochemical advantages over acyclic 
molecules in modulation of problematic molecular targets7 and decreasing binding affinity by 
the preorganization of bioactive conformations.8 The physiochemical advantages of 
macrocycles result from their structure, lower rotatable bond-count and ability to mask polar 
functionality by forming stable intramolecular H-bonds in low-dielectric environment.9 
Macrocyclic compounds containing highly reactive functional groups are particularly 
interesting as they provide an opportunity to modulate the physical and chemical properties 
of the compound. Such macrocycles possess structure-specific interactions and are therefore 
highly selective for their target molecules.10 
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As discussed in Chapter 1, tetramic acids represent an important structural motif that 
is present in many bioactive natural products. There are abundant examples of macrocyclic 
natural products containing a tetramic acid moiety in the literature that have excellent 
biological activities (Figure 2.2). Some of them are described here: Macrocidins A and B, 
both are acyltetramic acid isolated from Phoma macrostoma and are inhibitors of weeds 
growth and chlorosis.11 Cylandrimide A, which is extracted from the Halichondria sponge, is 
potent against various cancer cell lines.12 HSAF (heat-stable antifungal factor) is a known 
herbicide that controls plant fungal disease in agriculture and are also known to inhibit 
several fungal pathogens.13  Frontalamides A and B were discovered from Streptomyces 
species while Frontalamide FI-2 was obtained by genetic engineering on Streptomyces 
species14. All variants of this macrocyclic tetramic acid family show antifungal activity. 
Clifednamides are also macrocyclic tetramic acid analogs obtained by genetic engineering 
from the strain of Streptomyces species and display antifungal activity.15 Discodermide has 
been isolated from Discodermia species and is known to possess cytotoxic and antifungal 
properties.16 Ikarugamycin is a macrocyclic antibiotic isolated from Streptomyces species of 
symbiotic bacteria and demonstrates potent antiprotozoal activity as well as cytotoxic effects 
in cancer cell lines via genotoxicity and caspase activation ultimately leading to apoptosis.17 
Aburatubolactam A is a tetramic acid containing a macrolactam and is isolated form the 
bacteria of Streptomyces species found in marine mollusk.18 Aburatubolactam A is known to 
possess cytotoxicity, antimicrobial activity and the inhibition of superoxide generation. 
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Figure 2.2: Macrocyclic natural products having tetramic acid core. 
2.1.2 Synthesis: Macrocidin and macrocidin-like molecules 
Macrocidin has garnered lots of interest in the synthetic world since it was first 
isolated from the liquid culture of Phoma macrostoma that was obtained from a diseased 
Canada thistle.11 The interest was mainly because of its selective activity on broadleaf weeds 
while remaining inactive on grass weeds. Several attempts have been put forward for the 
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synthesis of Macrocidin and in these attempts; some of macrocidin-like molecules have also 
been made and tested for biological activity.19 
In 2006, Ramana and coworkers attempted to synthesize des-methylmacorcidin A 
using PMB-protected O-allyl-L-tyrosine methyl ester 2.1.1 and protected β-keto ester 2.1.2 to 
afford the β-ketoamide 2.1.3 (Scheme 2.1)20. The diene 2.1.3 was subjected to Lacey–
Dieckmann cyclization condition to obtain the RCM precursor containing tetramic acid core 
2.1.4 in 91% yield. G-II-catalyzed RCM on diene 2.1.4 afforded the macrocidin analog 2.1.6 
in poor yield. In an alternative strategy, 2.1.3 was first subjected to a G-I catalyzed RCM to 
form the macrocycle 2.1.5 with a good yield of 63%, followed by t-butoxide-mediated 
cyclization, to obtain des-methylmacrocidin A 2.1.6 in good yield. The authors also 
mentioned that they were unsuccessful in both Lacey–Dieckmann cyclization and RCM,  
 
Scheme 2.1: Synthesis of des-methylmacrocidin A. 
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without PMB-protection of the amine functional group. Although several attempts were 
made to install the epoxide in 2.1.6, none of them were successful as the starting material 
was decomposing in all the cases. 
In 2010, Schobert and coworkers demonstrated the synthesis of nor-macrocidin A 
based on C3-acylation of tyrosine-derived tetramic acid 2.2.1, followed by Williamson 
etherification (Scheme 2.2).21 For proof-of-concept, the authors started with the  
bis-protected tyrosine 2.2.1 to generate the corresponding tetramic acid 2.2.2 using 
Meldrum’s acid. Subsequent acylation with ω-bromo acid at the C3 position of 2.2.2 afforded 
the C3-acylated tetramic acids 2.2.3. Pd(PPh3)4 was used for deallylation of 2.2.3, which 
promoted in situ etherification via the phenolate anion, to afford macrocycle 2.2.4. 
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Scheme 2.2: Synthesis of Macrocidin like molecule 2.2.4. 
After successful synthesis of tetramic acid macrocycle 2.2.4, the authors applied a 
similar strategy to synthesize nor-macrocidin A 2.3.2 using the acetonide-bearing ω-bromo 
acid 2.3.6 and tyrosine-derived tetramic acid 2.2.2 (Scheme 2.3). For the synthesis of 2.3.6, 
the authors used caprolactone 2.3.3 and reduced it to the corresponding lactol, followed by 
Wittig alkenylation, and PMB-protection to afford 2.3.4. The resulting olefin was subjected 
to asymmetric dihydroxylation using AD-mix, followed by acetonide protection of diol and 
LiAlH4 reduction of ester to yield the corresponding primary alcohol 2.3.5. The resulting 
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alcohol was converted to the corresponding bromide in a couple of steps. DDQ-mediated 
PMB-deprotection and oxidation of the resulting alcohol using PDC furnished the 
corresponding carboxylic acid within the coupling partner 2.3.6. 
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Scheme 2.3: Synthesis of nor–Macrocidin A. 
In 2010, Suzuki and coworkers reported the first total synthesis of Macrocidin A 
(Scheme 2.4).22 The authors started their synthesis with propargyl alcohol to generate the 
desired acid for reaction with tyrosine. In two steps, propargyl alcohol was converted to 
allylic alcohol and next to epoxide 2.4.2 using the Katsuki-Sharpless asymmetric 
epoxidation. The primary alcohol was protected as silyl ether before subjecting the 
compound to an Rh-catalyzed hydroboration-oxidation sequence, which was followed by 
Swern oxidation to furnish aldehyde 2.4.3. Horner-Emmons olefination with phosphonate 
2.4.4, followed by desilylation and epoxide ring opening, yielded the 1,3-diol 2.4.5. The 
desired epoxy alcohol 2.4.6 was synthesized from 2.4.5 using an Ir-catalyzed asymmetric 
hydrogenation. Final regeneration of the epoxide was accomplished using potassium 
carbonate in MeOH. 
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Scheme 2.4: Total synthesis of macrocidin A 
With 2.4.6 in hand, the authors coupled with bis-N-protected tyrosine precursor 2.4.7 
using Mitsunobu conditions. Next, TBAF-mediated deprotection of the 2-(trimethylsilyl) 
ethoxycarbonyl (Teoc) group was performed to furnish the macrolactam precursor, which 
was next subjected to acyl-ketene cyclization in refluxing toluene to afford macrocycle 2.4.8. 
Lacey–Dieckmann cyclization on macrolactam 2.4.8 using KOtBu in t-butanol provided the 
tetramic acid core. The final product, macrocidin A (2.4.9) was obtained by the deprotection 
of the PAB-group using hydrogenation conditions, followed by treatment with DDQ. 
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In 2016, Schobert and coworkers reported the total synthesis of macrocidin A 
(Scheme 2.5).23 The authors started the synthesis of side chain fragment 2.5.5 from  
5-bromovaleric acid 2.5.1, which was converted to a mixed anhydride and allowing coupling 
with the Evans auxiliary, followed by enolate formation, and subsequent methylation to 
furnish 2.5.2 in 84% yield. This intermediate 2.5.2 was subjected to Finkelstein halogen 
exchange, followed by in situ generation of the organozincate, which on Pd(0) catalyzed 
coupling with vinyl iodide, afforded 2.5.3. Removal of the auxiliary from intermediate 2.5.3 
followed by silyl deprotection and diastereoselective Sharpless epoxidation furnished epoxy 
alcohol 2.5.4. Epoxy alcohol was mesylated and converted to the corresponding bromide 
using LiBr. The desired carboxylic acid 2.5.5 was obtained by hydrogenolytic cleavage of the 
benzyl ester. After the synthesis of the side-chain fragment, the next step was coupling with 
tyrosine. To commence the coupling step, the authors used O-allylated tyrosine 2.6.1 and 
treated with Meldrum’s acid in the presence of EtOAc to construct the tetramic acid core 
within 2.6.2 (Scheme 2.6). The tetramate 2.6.2 was next coupled with the carboxylic acid 
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Scheme 2.5: Synthesis of epoxy bromide. 
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2.5.5 to furnish the 4-O-acyltetramate 2.6.3, which subsequently underwent a Fries-type acyl 
rearrangement, to furnish 3-acyltetramic acid 2.6.4. The final step in the total synthesis of 
macrocidin A was Pd(0)-catalyzed deallylation of 2.6.4 followed by Williamson 
etherification to achieve the desired product 2.6.5. 
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Scheme 2.6: Synthesis of macrocidin A via Williamson’s etherification. 
2.2 Results 
Inspired by the potent bioactivities of macrocyclic tetramic acid, more specifically 
macrocidin A, sulfonamides and sultams, we are interested in the design and synthesis of 
macrocyclic β-keto vinyl sultam analogs of tetramic acids that can be modulated 
electronically, sterically and stereochemically. We also aim for future reactivity profiling 
studies of these novel S-containing unsaturated macrocyclic electrophiles with thiols and 
cysteine residues to test our hypothesis of them being used as macrocyclic covalent 
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inhibitors. Our ultimate aim is to use these compounds as probes that can target the shallow 
binding sites of rare protein residues and enzymes. 
2.2.1 Synthetic design of sultam analogs of macrocidin A-like molecule 
Our lab has been interested in the synthesis of diverse sultam scaffolds as discussed 
earlier in chapter 1. Along this line, we have designed the synthesis of sulfur containing 
macrocyclic compounds. Such compounds will help in comparative and comprehensive 
ranking of elaborate electrophilic compounds, such as macrocycles bearing complex 
stereochemical arrays, structural conformations, ring size, and attenuated S-warheads. 
Our design is based on the synthesis of a tyrosine-derived tetramic acid, which can be 
achieved by esterification, O-allylation/propargylation, mesylation, N-benzylation and 
cyclization of tyrosine (Figure 2.3). Once the tyrosine-derived tetramic acid is formed, 
macrocyclization is envisioned via a ring-closing metathesis (RCM) reaction (2.3-A and 2.3-
C) or intra molecular click (IM click) reaction (2.3-B and 2.3-D). The reactivity of the 
resulting macrocycles will be assessed using different thiol- and oxo-nucleophiles and the 
progression of the reactions will be monitored by 1H, 19F NMR and LC-MS. 
2.2.2 Synthesis of sultam analogs of macrocidin A-like molecule 
Our synthesis commenced with the generation of tyrosine methyl ester 2.7.2 by the 
reaction of L-tyrosine 2.7.1 and thionyl chloride in MeOH and heating the reaction mixture at 
60 ˚C for 6 hours (Scheme 2.7). The solvent, MeOH, was evaporated under reduced pressure 
and the reaction mixture was directly subjected to TBS-protection of the phenol moiety.  This 
method gave us 37% yield of the TBS-protected L-tyrosine methyl ester 2.7.3. 
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Figure 2.3: Design and synthetic strategy for the synthesis of macrocidin-like compound. 
We realized that the low yield of 2.7.3 might be due to the protonation of 2.7.2 by the 
HCl formed during esterification. So, the reaction mixture of esterification reaction was 
washed with water and extracted with EtOAc several times until the aqueous portion did not 
show the presence of the compound by TLC. This improvised procedure yielded 77% over 
two steps. The next step involved simple mesylation of 2.7.3, which was accomplished by 
use of MsCl and Et3N to generate the mesylated tyrosine derivative 2.7.4. 
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Scheme 2.7: Synthesis of mesylated L-tyrosine methyl ester. 
Compound 2.7.4 was N-benzylated using several substituted benzyl bromides in the 
presence of potassium carbonate as base to furnish 2.8.1 (Scheme 2.8). The acyclic 
intermediate 2.8.1 was then subjected to Dieckmann-type cyclization conditions. In this 
method, the compound was dissolved in dry THF and the temperature was lowered to -78 ˚C, 
then LiHMDS was added dropwise to the cold reaction mixture to generate the tetramic acid 
analog 2.8.2. The reaction was very sensitive to moisture as any hint of moisture in the 
reaction medium completely prevented the reaction, resulting in full recovery of starting 
material. The TBS-protected phenol of tetramic acid analog 2.8.2 was deprotected using 
TBAF in THF to afford the β-keto sulfonamide 2.8.3. 
Our next step towards macrocyclization was to introduce an allyl group to the phenol 
of 2.8.3. Several attempts of allylation gave unsatisfactory low yields (<27%) with multiple 
spots in TLC.  After obtaining multiple spots in the TLC across several runs, combined with 
a low yield of the desired product, we reasoned that we were generating more than one 
nucleophilic site within the starting material (ie, the pKa of phenol is roughly equal to or 
lower than the proton at the C3 position of the sultam tetramate 2.8.3).  Therefore, to avoid 
competitive reactions, we took an alternative approach. 
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Scheme 2.8: Tyrosine derived β-keto sultam. 
We decided to install the allyl group prior to Dieckmann cyclization. Hence 
compound 2.8.1 was treated with TBAF in THF to deprotect the TBS group to generate 
2.9.1, which was subsequently allylated using allyl bromide in the presence of K2CO3 with 
refluxing in CH3CN to generate compound 2.9.2. Subsequent Dieckmann cyclization of 2.9.2 
afforded β-keto sulfonamide 2.9.3. 
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Scheme 2.9: Synthesis of β-keto sultam. 
Besides tyrosine, serine was also used for the purpose of macrocyclization (Scheme 
2.10). Similar sets of reactions, as performed with tyrosine, were conducted in an attempt to 
obtain a serine-based macrocycle. It will be interesting to see the differences in the properties 
of these macrocycles and their roles as electrophilic probes. 
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Scheme 2.10: Synthesis of mesylated L-serine methyl ester. 
With construction of the β-keto sulfonamide core, we next needed an aldehyde to 
couple with the allylated tetramic acid 2.9.3. Several aldehydes with varying chain lengths 
were made using 3-hydroxybenzaldehyde 2.11.1 (Scheme 2.11). The aldehyde 2.11.1 was 
reacted with allyl bromide and two other terminal alkene bromides to generate the O-
substituted 3-hydroxy aldehydes 2.11.2–2.11.5. The substituted aldehyde 2.11.8 was formed 
by reacting 2.11.1 with tosylated allyloxyethanol 2.11.7 in the presence of cesium carbonate 
(Cs2CO3). 
HO
O
TsCl, Et3N, DMAP
CH2Cl2, 0 °C to rt
89%
TsO
O Cs2CO3, DMF
90 °C, 76%
CHO
OH
CHO
O
O
CHO
O
CHO
OH
Br
K2CO3, MeCN
80 °C, 6 - 8 h
84-86 %
n
n
n = 1-3
CHO
O
CHO
O
CHO
O
2.11.1 2.11.2 2.11.3 2.11.4 2.11.5
2.11.6 2.11.7
2.11.1
2.11.8  
Scheme 2.11: Synthesis of O-substituted 3-hydroxy aldehydes. 
With the desired aldehydes in hand, we coupled aldehyde 2.11.3 with the allylated β-
keto sulfonamide 2.12.1 using the aforementioned Knoevenagel conditions (Chp-1) 
employing L-proline as a catalyst in the polar protic solvent trifluoroethanol. After 12 h of 
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stirring at 50 ˚C, the coupled product 2.12.2 was obtained in 34% yield (Scheme 2.12). The 
lower yield was mainly due to a challenge in purification of this product. It was observed that 
the product was highly unstable on silica gel and converted back to starting material during 
column separation. Several modification and alternatives were tried to enhance the yield of 
the reaction, such as use of neutral alumina, using small amount of 0.1% acetic acid or 0.1% 
of triethyl amine to column. So far, we were not able to increase the yield of the 
Knoevenagel condensation reaction. 
Our attempt of RCM of 2.12.2 remained unsuccessful. Several cyclization conditions 
were investigated, the first of which consisted of 5 mol% of Grubbs II catalyst in CH2Cl2 and 
refluxing for an hour. Further optimizations were done by increasing the amount of catalyst 
to 15 mol% as well as changing the solvent to toluene. In all these cases decomposition of 
starting material was observed. These failures prompted us to question the stereochemistry at 
the olefin of the Knoevenagel products, and drove the aforementioned X-ray and NMR 
studies outlined at the end of Chapter 1, where we were able to obtain crystals of some of the 
unsaturated β-keto sultams. As noted before, the X-ray crystal structure of those compounds  
 
Scheme 2.12: Knoevenagel condensation of β-keto sulfonamide and aldehyde. 
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revealed the ‘Z’ configuration (Fig 1.13, Chapter-1). On the basis of the X-ray structure of 
2.4-A and 2.4-B we rationalized that the Knoevenagel condensation of β-keto sultams 2.12.1 
did not result in the formation of desired E-olefin 2.12.3, but rather the Z-olefin was 
obtained.  This finding was contrary to our targeted compound and was one of the possible 
reasons for RCM failure. 
 
 
Figure 2.4: X-ray crystal structures of -keto vinyl sultams 
2.3 Future work 
 (i) After revealing the stereochemistry at the olefin position, we are now aiming to 
perform RCM by installing a terminal olefinic N-substituent rather than at the side-chain as 
shown in Figure 2.5. After the synthesis of the macrocyclic β-keto vinyl sultams, preliminary  
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reactivity profiling studies will be performed in our lab with thiols and cysteine residue as 
well as ABPP studies in the laboratories of our collaborators. 
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Figure 2.5: Proposed alternative approach towards macrocyclic β-keto vinyl sultam analogs. 
  2.4 Conclusion 
In summary, an attempt towards the synthesis of macrocidin-like -keto vinyl sultams 
has been reported along with the potential modification for successful synthesis. The 
synthetic route commences with L-tyrosine followed by N-mesylation, O-allylation,  
N-benzylation, Dieckmann type cyclization, and Knovenagel condensation. After identifying 
the probable cause for unsuccessful RCM, an alternative synthetic method has been proposed 
for macrocyclization, and will be reported in due course. 
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General Experimental Section 
All air and moisture sensitive reactions were carried out in flame- or oven-dried glassware 
under argon atmosphere using standard gas tight syringes and septa. Stirring was achieved with 
oven-dried, magnetic stir bars. THF and CH2Cl2 were purified by passage through a 
purification system (Solv-Tek) employing activated Al2O3 (Pangborn, A. B.; Giardello, M. A.; 
Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Safe and Convenient Procedure for Solvent 
Purification. Organometallics 1996, 15, 1518–1520). Et3N was purified by passage over basic 
alumina and stored over KOH. All olefin metathesis catalysts were acquired from Materia and 
used without further purification. Flash column chromatography was performed with SiO2 
obtained from Sorbent Technologies (30930M–25, Silica Gel 60 Å, 40–63 m). Thin layer 
chromatography was performed on silica gel 60F254 plates (EM–5717, Merck). Deuterated 
solvents were purchased from Cambridge Isotope laboratories. 1H, 19F, and 13C NMR spectra 
were recorded on a Bruker DRX–400 spectrometer operating at 400 MHz and 100 MHz 
respectively; or a Bruker DRX 500 operating at 500 MHz and 125 MHz respectively using 
CDCl3 or Methanol–d4 as solvents. Chemical shift values (δ) are reported in ppm (residual 
chloroform δ = 7.26 ppm and 77.0 ppm for 1H and 13C respectively). The 1H spectra are 
reported as follows δ (multiplicity, coupling constant J, number of protons). High-resolution 
mass spectrometry (HRMS) was recorded on an LCT Premier Spectrometer (Micromass UK 
Limited) operating on ESI (MeOH). Melting points were obtained on a Thomas Hoover 
capillary melting point apparatus. FTIR spectroscopy was performed using a Shimadzu FTIR-
8400S instrument. Observed rotations at 589 nm, were measured using AUTOPOL IV Model 
automatic polarimeter.  
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General Procedure A: To the solution of amino ester (1.0 equiv.) in CH2Cl2 (0.2 M), was 
added Et3N (3.0 equiv.) at 0 ˚C. After 15 min of stirring, methanesulfonyl chloride (2.0 equiv.) 
was added to the reaction mixture, and the reaction was stirred for 15 min at 0 ˚C and warmed 
to room temperature. After 6 h, the reaction was quenched with water and extracted with 
CH2Cl2 (3x). The organic layer was washed with brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure. 
General Procedure B: To the solution sulfonamide (1.0 equiv.) in MeCN (0.2 M), was added 
K2CO3 (3.0 equiv.) at room temperature. After 15 min of stirring, benzyl or allyl bromide (1.5 
equiv.) was added to the reaction mixture, and the reaction was heated to 80 ˚C. After 14 h, 
MeCN was removed under reduced pressure and the compound was extracted with CH2Cl2 
(3x). The organic layer was washed with brine, dried (MgSO4), filtered, and concentrated under 
reduced pressure. 
General Procedure C: To the solution of N–benzylated sulfonamide (1.0 equiv.) in dry THF 
(0.05 M), was added LiHMDS (3.0 equiv.) at -78 ˚C under argon atmosphere. After 2 h, the 
reaction mixture was quenched with saturated ammonium chloride solution and the compound 
was extracted with EtOAc (3x). The organic layer was washed with brine, dried (MgSO4), 
filtered, and concentrated under reduced pressure. 
General Procedure D: To the solution of tetramic acid analog (0.20 mmol, 1.0 equiv.) in 
2,2,2-trifluoroethanol (1.5 ml), was added L-proline (20 mol%) at 50 ˚C. After 15 min of 
stirring, aldehyde (0.22 mmol, 1.1 equiv.) was added and stirred overnight at 50 ˚C. The 
reaction mixture was removed from heating and after it reached the room temperature, the 
reaction vessel was kept in ice-cold water. The precipitate formed was then washed with 
ethanol and hexane (3x each) to afford the product. If the product did not precipitate, the 
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reaction mixture was evaporated, and the compound was extracted with EtOAc (3x). The 
organic layer was washed with brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure.  
General Procedure E: To the solution of amino ester (1.0 equiv.) in THF (0.2 M) at 0 ˚C, was 
added Et3N (3.0 equiv.) followed by DMAP (20 mol%). After 15 min of stirring, TBSCl (2.5 
equiv.) was added to the reaction mixture and refluxed overnight. The reaction mixture was 
quenched with water and extracted with EtOAc (3x). The organic layer was washed with brine, 
dried (MgSO4), filtered, and the solvent removed under reduced pressure. 
General Procedure F: To the solution of protected amino ester (1.0 equiv.) in THF (0.2 M) 
at 0 ˚C, was added TBAF (2.5 equiv.) dropwise. After 15 min of stirring, the reaction was 
brought to room temperature. After 2 h, the reaction was quenched with saturated ammonium 
chloride and the compound was extracted with EtOAc (3x). The organic layer was washed 
with brine, dried (MgSO4), filtered, and concentrated under reduced pressure. 
Methyl (methylsulfonyl)-L-phenylalaninate (1.22.3a) 
 
According to general procedure A; flash chromatography (100% Hexane to 15% EtOAc in 
Hexane) provided 1.22.3a (2.1 g, 89%) as a pale-yellow oil. 
TLC Rf = 0.4 (2:1 Hexanes/EtOAc) [α]25D = -29.7 (c = 2.1, CHCl3) 
HRMS calculated for C11H15NO4SNa (M+Na)
+ 280.0620; found 280.0627 (TOF MS ES+) 
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FTIR (neat): 3251, 1738, 1607, 1348, 1170 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.39 – 7.23 (m, 3H), 7.23 – 7.17 (m, 2H), 5.14 (d, J = 9.3 Hz, 
1H), 4.38 (ddd, J = 9.3, 7.7, 5.1 Hz, 1H), 3.77 (s, 3H), 3.16 (dd, J = 13.7, 5.1 Hz, 1H), 2.99 
(dd, J = 13.8, 7.7 Hz, 1H), 2.63 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 172.1, 135.7, 129.6, 128.9, 127.5, 57.3, 52.8, 41.3, 39.4. 
Methyl (S)-2-(methylsulfonamido)-3-(4-nitrophenyl)propanoate (1.22.3b) 
 
According to general procedure A; flash chromatography (5% EtOAc in Hexane to 25% 
EtOAc in Hexane) provided 1.22.3b (3.25 g, 85%) as a pale orange solid. 
MP = 174 – 176 ˚C; TLC Rf = 0.3 (2:1 Hexanes/EtOAc) [α]25D = 27.7 (c =1.1, CHCl3) 
HRMS calculated for C11H14N2O6SNa (M + Na)
+ 325.0470; found 325.0478 (TOF MS ES+) 
FTIR (KBr film): 3251, 1738, 1607, 1524, 1348, 1170 cm-1 
1H NMR ((CD3)2CO, 400 MHz) δ 8.23 – 8.17 (m, 2H), 7.65 – 7.59 (m, 2H), 4.43 (ddd, J = 9.1, 
5.6, 3.5 Hz, 1H), 3.74 (s, 3H), 3.34 (dd, J = 13.8, 5.5 Hz, 1H), 3.17 (dd, J = 13.8, 8.7 Hz, 1H), 
2.77 (d, J = 1.2 Hz, 3H). 
13C NMR ((CD3)2CO, 126 MHz) δ 172.4, 148.1, 145.9, 131.8, 124.3, 57.8, 52.9, 41.5, 39.2. 
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Methyl N-(4-chlorobenzyl)-N-(methylsulfonyl)-L-phenylalaninate (1.22.4a) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 20% EtOAc 
in Hexane) provided 1.22.4a (3.32 g, 94%) as a pale-yellow oil. 
TLC Rf = 0.4 (4:1 Hexanes/EtOAc) [α]25D = -33.74 (c = 2.8, CHCl3) 
HRMS calculated for C18H20ClNO4SNa (M + Na)
+ 404.0699; found 404.0704 (TOF MS ES+) 
FTIR (neat): 3231, 1732, 1604, 1348, 1170 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.36 – 7.21 (m, 7H), 7.17 – 7.06 (m, 2H), 4.78 (dd, J = 8.6, 6.8 
Hz, 1H), 4.49 (d, J = 15.9 Hz, 1H), 4.28 (d, J = 15.9 Hz, 1H), 3.66 (s, 3H), 3.26 (dd, J = 14.4, 
6.9 Hz, 1H), 2.99 (dd, J = 14.4, 8.6 Hz, 1H), 2.75 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 171.1, 136.8, 134.9, 133.9, 130.1, 129.2, 128.7, 128.7, 127.0, 
61.8, 52.5, 49.3, 40.2, 36.9. 
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Methyl (S)-2-(N-(4-chlorobenzyl)methylsulfonamido)-3-(4-nitrophenyl)propanoate 
(1.22.4b) 
 
According to general procedure B; flash chromatography (10%EtOAc in Hexane to 30% 
EtOAc in Hexane) provided 1.22.4b (3.2 g, 94%) as a pale-orange solid. 
Mp = 103 – 105 ˚C; TLC Rf = 0.3 (1:1 Hexanes/EtOAc) [α]25D = -27.7 (c = 0.7, CHCl3) 
HRMS calculated for C18H19ClN2O6SNa (M + Na)
+ 449.0550; found 449.0559 (TOF MS ES+) 
FTIR (KBr Film): 1749, 1606, 1520, 1352, 1144 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.13 – 7.97 (m, 2H), 7.24 – 7.13 (m, 6H), 4.74 (dd, J = 8.3, 7.0 
Hz, 1H), 4.50 (d, J = 15.7 Hz, 1H), 4.19 (d, J = 15.7 Hz, 1H), 3.76 (s, 3H), 3.27 (dd, J = 14.6, 
7.0 Hz, 1H), 3.01 (dd, J = 14.6, 8.4 Hz, 1H), 2.96 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 170.5, 147.0, 144.4, 134.7, 134.4, 130.2, 130.0, 128.9, 123.7, 
61.54, 52.9, 49.9, 40.2, 37.3. 
Methyl N-benzyl-N-methylsulfonyl-L-phenylalaninate (1.22.4c) 
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According to general procedure B; flash chromatography (5% EtOAc in Hexane to 20% EtOAc 
in Hexane) provided 1.22.4c (1.12 g, 89%) as a pale-yellow oil. 
TLC Rf = 0.6 (2:1 Hexanes/EtOAc) [α]25D = -55.4 (c = 2.8, CHCl3) 
HRMS calculated for C18H21NO4SNa (M + Na)
+ 370.1089; found 370.1103 (TOF MS ES+) 
FTIR (neat): 1748, 1609, 1353, 1175 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.32 – 7.14 (m, 8H), 7.11 – 6.98 (m, 2H), 4.68 (dd, J = 8.2, 7.1 
Hz, 1H), 4.44 (d, J = 15.6 Hz, 1H), 4.23 (d, J = 15.6 Hz, 1H), 3.55 (s, 3H), 3.20 (dd, J = 14.3, 
7.0 Hz, 1H), 2.95 (dd, J = 14.3, 8.2 Hz, 1H), 2.65 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 1701.0, 137.1, 136.1, 129.3, 128.8, 128.6, 128.6, 128.0, 
126.9, 61.8, 52.3, 49.9, 40.4, 36.9. 
Methyl (S)-2-(N-benzylmethylsulfonamido)-3-(4-nitrophenyl)propanoate (1.22.4d) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 1.22.4d (1.84 g, 87%) as an orange solid. 
Mp = 77 – 78 ˚C; TLC Rf = 0.4 (2:1 Hexanes/EtOAc) [α]25D = -37.5 (c = 1.2, CHCl3) 
HRMS calculated for C18H20N2O6SNa (M + Na)
+ 415.0940; found 415.0945 (TOF MS ES+) 
FTIR (KBr Film): 1743, 1606, 1515, 1345, 1147 cm-1 
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1H NMR (CDCl3, 400 MHz) δ 8.07 – 7.69 (m, 2H), 7.21 – 7.06 (m, 5H), 7.04 – 6.88 (m, 2H), 
4.56 (dd, J = 8.3, 6.8 Hz, 1H), 4.35 (d, J = 15.4 Hz, 1H), 4.09 (d, J = 15.5 Hz, 1H), 3.60 (s, 
3H), 3.14 (dd, J = 14.5, 6.8 Hz, 1H), 2.90 (dd, J = 14.5, 8.4 Hz, 1H), 2.81 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 170.5, 146.9, 144.7, 135.9, 130.1, 128.9, 128.8, 128.3, 123.6, 
61.6, 52.8, 50.7, 40.2, 37.2. 
Methyl N-(4-fluorobenzyl)-N-(methylsulfonyl)-L-phenylalaninate (1.22.4e) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 1.22.4e (1.16 g, 88%) as a pale-yellow solid. 
Mp = 93 – 95 ˚C; TLC Rf = 0.6 (2:1 Hexanes/EtOAc) [α]25D = -44.7 (c = 1.7, CHCl3) 
HRMS calculated for C18H20FNO4SNa (M + Na)
+ 388.0995; found 388.1010 (TOF MS ES+) 
FTIR (KBr Film): 1737, 1606, 1352, 1148 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.26 – 7.17 (m, 5H), 7.12 – 7.03 (m, 2H), 6.98 – 6.87 (m, 2H), 
4.72 (dd, J = 8.6, 6.8 Hz, 1H), 4.42 (d, J = 15.7 Hz, 1H), 4.23 (d, J = 15.7 Hz, 1H), 3.58 (s, 
3H), 3.20 (dd, J = 14.4, 6.8 Hz, 1H), 2.94 (dd, J = 14.4, 8.6 Hz, 1H), 2.66 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 171.0, 162.4 (d, J = 246.2 Hz), 136.8, 132.0 (d, J = 2.9 Hz), 
130.5 (d, J = 8.1 Hz), 129.1, 128.6, 126.9, 115.3 (d, J = 21.7 Hz), 61.6, 52.4, 49.1, 40.1, 36.8. 
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Methyl (S)-2-(N-(4-fluorobenzyl)methylsulfonamido)-3-(4-nitrophenyl)propanoate 
(1.22.4f) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 1.22.4f (2.00 g, 91%) as a pale-yellow solid. 
Mp = 113 – 114 ˚C; TLC Rf = 0.4 (2:1 Hexanes/EtOAc) [α]25D = -51.7 (c = 1.2, CHCl3) 
HRMS calculated for C18H19FN2O6SNa (M + Na)
+ 433.0846; found 433.0862 (TOF MS ES+) 
FTIR (KBr Film): 1747, 1605, 1519, 1350, 1145 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.10 – 8.01 (m, 2H), 7.27 – 7.22 (m, 2H), 7.18 – 7.13 (m, 2H), 
6.98 – 6.91 (m, 2H), 4.74 (dd, J = 8.3, 6.9 Hz, 1H), 4.49 (d, J = 15.6 Hz, 1H), 4.20 (d, J = 15.6 
Hz, 1H), 3.75 (s, 3H), 3.27 (dd, J = 14.5, 7.0 Hz, 1H), 3.01 (dd, J = 14.5, 8.3 Hz, 1H), 2.95 (s, 
3H). 
13C NMR (CDCl3, 126 MHz) δ 170.5, 162.7 (d, J = 247.5 Hz), 147.0, 144.5, 131.9 (d, J = 3.5 
Hz), 130.6 (d, J = 8.2 Hz), 130.1, 123.7, 115.7 (d, J = 21.1 Hz), 61.5, 52.9, 49.8, 40.2, 37.2. 
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(S)-3-benzyl-2-(4-chlorobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5a) 
 
According to general procedure C; flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 1.22.5a (0.65 g, 51%) as a pale-orange solid. 
Mp = 126 – 128 ˚C; TLC Rf = 0.6 (4:1 Hexanes/EtOAc) [α]25D = -21.3 (c = 1.1, CHCl3) 
HRMS calculated for C17H17ClNO3S (M + H)
+ 350.0618, found 350.0624 (TOF MS ES+) 
FTIR (KBr Film): 1755, 1596, 1372, 1186 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.36 – 7.21 (m, 5H), 7.17 – 7.10 (m, 2H), 7.06 – 6.99 (m, 2H), 
4.58 (d, J = 15.2 Hz, 1H), 3.92 (ddd, J = 8.2, 4.4, 1.3 Hz, 1H), 3.84 (d, J = 15.1 Hz, 1H), 3.69 
(d, J = 16.6 Hz, 1H), 3.60 (dd, J = 16.6, 1.4 Hz, 1H), 3.14 (dd, J = 14.1, 4.4 Hz, 1H), 3.06 (dd, 
J = 14.2, 8.2 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 198.1, 135.7, 134.7, 132.5, 130.5, 129.6, 129.3, 129.1, 127.6, 
69.3, 55.9, 47.5, 37.3. 
(S)-2-(4-chlorobenzyl)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5b) 
 
 
97 
 
According to general procedure C; flash chromatography (100% Hexane to 15% EtOAc in 
Hexane) provided 1.22.5b (0.35 g, 54%) as an orange solid. 
Mp = 136 – 138 ˚C; TLC Rf = 0.7 (2:1 Hexanes/EtOAc) [α]25D = -12.6 (c = 0.1, CHCl3) 
HRMS calculated for C17H16ClN2O5S (M + H)
+ 395.0468, found 395.0475 (TOF MS ES+) 
FTIR (KBr Film): 1767, 1606, 1516, 1345, 1183 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.14 – 8.09 (m, 2H), 7.25 – 7.20 (m, 4H), 7.07 – 7.02 (m, 2H), 
4.39 (d, J = 14.9 Hz, 1H), 4.11 (d, J = 14.9 Hz, 1H), 3.97 (dd, J = 7.9, 5.5 Hz, 1H), 3.73 (s, 
2H), 3.18 (dd, J = 6.7, 3.4 Hz, 2H). 
13C NMR (CDCl3, 126 MHz) δ 198.1, 147.4, 143.2, 135.1, 132.3, 130.5, 130.5, 129.4, 124.0, 
69.8, 55.3, 49.8, 37.1. 
(S)-2,3-dibenzylisothiazolidin-4-one 1,1-dioxide (1.22.5c)  
 
According to general procedure C; flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 1.22.5c (0.56 g, 50%) as a pale-orange solid. 
Mp = 87 – 89 ˚C; TLC Rf = 0.6 (4:1 Hexanes/EtOAc) [α]25D = -11.2 (c =1.0, CHCl3) 
HRMS calculated for C17H17NO3SNa (M + Na)
+ 338.0827, found 338.0844 (TOF MS ES+) 
FTIR (KBr film): 3031, 2934, 1754, 1373, 1137 cm-1 
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1H NMR (CDCl3, 400 MHz) δ 7.37 – 7.23 (m, 6H), 7.15 – 6.98 (m, 4H), 4.66 (d, J = 15.0 Hz, 
1H), 3.90 (ddd, J = 7.9, 4.7, 1.4 Hz, 1H), 3.76 (d, J = 15.0 Hz, 1H), 3.62 (d, J = 16.5 Hz, 1H), 
3.51 (dd, J = 16.6, 1.3 Hz, 1H), 3.08 (dd, J = 14.1, 4.7 Hz, 1H), 3.01 (dd, J = 14.1, 7.8 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 198.4, 135.7, 133.94, 129.7, 129.3, 129.1, 129.0, 128.7, 
127.5, 68.9, 56.1, 48.0, 37.1. 
(S)-2-benzyl-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5d) 
 
According to general procedure C; flash chromatography (100% Hexane to 15% EtOAc in 
Hexane) provided 1.22.5d (0.90 g, 55%) as an orange solid. 
Mp = 132 – 135 ˚C; TLC Rf = 0.6 (2:1 Hexanes/EtOAc) [α]25D = -23.6 (c = 0.1, CHCl3) 
HRMS calculated for C17H16N2O5SNa (M + Na)
+ 383.0698, found 383.0706 (TOF MS ES+) 
FTIR (KBr film):  1747, 1602, 1524, 1332, 1164 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.07 (d, J = 8.4 Hz, 2H), 7.33 – 7.23 (m, 3H), 7.20 (d, J = 8.3 
Hz, 2H), 7.11 (d, J = 7.1 Hz, 2H), 4.45 (d, J = 14.7 Hz, 1H), 4.10 (d, J = 14.7 Hz, 1H), 4.00 (t, 
J = 6.6 Hz, 1H), 3.79 – 3.66 (m, 2H), 3.23 – 3.12 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 198.5, 147.3, 143.4, 133.7, 131.1, 130.5, 129.2, 128.9, 123.9, 
69.7, 55.4, 50.5, 37.1. 
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(S)-3-benzyl-2-(4-fluorobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5e) 
 
According to general procedure C; flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 1.22.5e (0.57 g, 53%) as a pale-orange solid. 
Mp = 116 – 117 ˚C; TLC Rf = 0.5 (4:1 Hexanes/EtOAc) [α]25D = -13.6 (c =0.1, CHCl3) 
HRMS calculated for C17H16FNO3SNa (M + Na)
+ 356.0733; found 356.0739 (TOF MS ES+) 
FTIR (KBr film): 1752, 1604, 1332, 1135 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.35 – 7.28 (m, 3H), 7.16 – 7.04 (m, 4H), 7.00 – 6.93 (m, 2H), 
4.61 (d, J = 15.1 Hz, 1H), 3.93 (ddd, J = 8.1, 4.4, 1.3 Hz, 1H), 3.83 (d, J = 15.1 Hz, 1H), 3.68 
(d, J = 16.6 Hz, 1H), 3.58 (dd, J = 16.6, 1.3 Hz, 1H), 3.14 (dd, J = 14.1, 4.4 Hz, 1H), 3.06 (dd, 
J = 14.1, 8.1 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 198.2, 162.8 (d, J = 247.9 Hz), 135.7, 131.0 (d, J = 8.2 Hz), 
129.8 (d, J = 3.5 Hz), 129.6, 129.0, 127.6, 116.0 (d, J = 21.1 Hz), 69.1, 55.9, 47.4, 37.2. 
(S)-2-(4-fluorobenzyl)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5f) 
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According to general procedure C; flash chromatography (100% Hexane to 15% EtOAc in 
Hexane) provided 1.22.5f (0.54 g, 56%) as a pale-orange solid. 
Mp = 134 – 135 ˚C; TLC Rf = 0.5 (2:1 Hexanes/EtOAc) [α]25D = -2.7 (c = 0.1, CHCl3) 
HRMS calculated for C17H16FN2O5S (M + H)
+ 379.0764; found 379.0782 (TOF MS ES+) 
FTIR (KBr film): 1769, 1606, 1509, 1344, 1134 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.17 – 8.04 (m, 2H), 7.28 – 7.20 (m, 2H), 7.15 – 7.06 (m, 2H), 
7.01 – 6.92 (m, 2H), 4.44 (d, J = 14.9 Hz, 1H), 4.07 (d, J = 14.9 Hz, 1H), 3.98 (dd, J = 7.5, 5.7 
Hz, 1H), 3.72 (d, J = 1.2 Hz, 2H), 3.18 (dd, J = 6.7, 2.5 Hz, 2H). 
13C NMR (CDCl3, 126 MHz) δ 198.1, 162.9 (d, J = 249.0 Hz), 147.4, 143.2, 131.0 (d, J = 8.2 
Hz), 130.6, 129.6 (d, J = 2.8 Hz), 124.0, 116.2 (d, J = 21.1 Hz), 69.6, 55.4, 49.5, 37.0. 
(S,E)-3-benzyl-2-(4-chlorobenzyl)-5-(4-methoxybenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1a) 
 
According to general procedure D; 1.27.1a (46.2 mg, 49%) precipitated as a yellow solid. 
Mp = 154 – 155 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -34.0 (c = 0.2, CHCl3) 
HRMS calculated for C25H22ClNO4SNa (M + Na)
+ 490.0856; found 490.0866 (TOF MS ES+) 
FTIR (KBr film): 1710, 1604, 1356, 1273, 1169, 1029 cm-1 
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1H NMR (CDCl3, 400 MHz) δ 8.14 – 7.98 (m, 2H), 7.79 (s, 1H), 7.29 (m, 3H), 7.21 – 7.15 (m, 
4H), 7.08 – 7.01 (m, 2H), 6.99 – 6.91 (m, 2H), 4.50 (d, J = 15.1 Hz, 1H), 3.96 (dd, J = 8.7, 4.9 
Hz, 1H), 3.92 (s, 3H), 3.88 (d, J = 15.1 Hz, 1H), 3.29 – 3.04 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 165.1, 145.5, 137.1, 136.4, 134.2, 133.0, 130.4, 129.7, 
128.99, 128.9, 127.3, 124.8, 123.2, 115.3, 67.8, 55.9, 47.8, 38.3. 
(S,E)-3-benzyl-2-(4-chlorobenzyl)-5-(4-fluorobenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1b) 
 
According to general procedure D; 1.27.1b (39 mg, 43%) precipitated as a yellow solid. 
Mp = 141 – 143 ˚C; TLC Rf = 0.32 (7:1 Hexanes/EtOAc) [α]25D = -11.6 (c = 0.2, CHCl3) 
HRMS calculated for C24H19ClFNO3SNa (M + Na)
+ 478.0656; found 478.0638 (TOF MS 
ES+) 
FTIR (KBr film): 1716, 1611, 1338, 1164 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.16 – 7.99 (m, 2H), 7.79 (s, 1H), 7.33 – 7.28 (m, 4H), 7.25 – 
7.15 (m, 5H), 6.98 – 6.88 (m, 2H), 4.52 (d, J = 15.0 Hz, 1H), 3.98 (dd, J = 8.4, 5.4 Hz, 1H), 
3.86 (d, J = 15.0 Hz, 1H), 3.22 – 3.07 (m, 2H). 
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13C NMR (CDCl3, 126 MHz) δ 190.2, 166.3 (d, J = 259.7 Hz), 143.9, 136.7 (d, J = 9.9 Hz), 
136.1, 134.4, 132.7, 130.4, 129.7, 129.1, 129.0, 127.6 (d, J = 2.7 Hz), 127.5, 126.7 (d, J = 2.8 
Hz), 117.1 (d, J = 22.7 Hz), 67.8, 47.9, 38.2. 
(S,E)-3-benzyl-5-benzylidene-2-(4-chlorobenzyl)isothiazolidin-4-one 1,1-dioxide 
(1.27.1c) 
 
According to general procedure D; 1.27.1c (0.37 g, 42%) precipitated as a yellow solid. 
Mp = 143 – 145 ˚C; TLC Rf = 0.4 (7:1 Hexanes/EtOAc) [α]25D = -14.7 (c = 0.1, CHCl3) 
HRMS calculated for C24H20ClNO3SNa (M + Na)
+ 460.0750; found 460.0762 (TOF MS ES+) 
FTIR (KBr film): 1721, 1594, 1339, 1163 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.11 – 8.02 (m, 2H), 7.85 (s, 1H), 7.69 – 7.59 (m, 1H), 7.59 – 
7.50 (m, 2H), 7.31 (qd, J = 3.2, 2.2 Hz, 3H), 7.22 – 7.14 (m, 4H), 7.00 – 6.86 (m, 2H), 4.51 (d, 
J = 15.0 Hz, 1H), 3.98 (dd, J = 8.1, 5.7 Hz, 1H), 3.87 (d, J = 15.0 Hz, 1H), 3.20 – 3.07 (m, 
2H). 
13C NMR (CDCl3, 126 MHz) δ 190.4, 145.5, 136.2, 134.3, 134.3, 134.0, 132.8, 130.4, 130.3, 
129.7, 129.6, 129.1, 129.0, 128.1, 127.4, 67.8, 48.0, 38.2. 
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(S,E)-2-(4-chlorobenzyl)-5-(4-fluorobenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 
1,1-dioxide (1.27.1d) 
 
According to general procedure D; 1.27.1d (0.36 g, 40%) precipitated as a yellow solid. 
Mp = 168 – 170 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -0.54 (c = 1.1, CHCl3) 
HRMS calculated for C24H18ClFN2O5SNa (M + Na)
+ 523.0607, found 523.0631 (TOF MS 
ES+) 
FTIR (KBr film):  1713, 1581, 1514, 1347, 1166, 1048 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.13 – 8.05 (m, 4H), 7.81 (s, 1H), 7.25 – 7.18 (m, 6H), 7.06 – 
7.01 (m, 2H), 4.35 (d, J = 14.9 Hz, 1H), 4.21 (d, J = 14.9 Hz, 1H), 4.02 (dd, J = 8.5, 5.0 Hz, 
1H), 3.24 (dd, J = 14.0, 8.5 Hz, 1H), 3.15 (dd, J = 14.1, 5.1 Hz, 1H). 
13C NMR (CDCl3, 126 MHz δ 190.0, 166.5 (d, J = 260.6 Hz), 147.3, 144.9, 143.3, 136.8 (d, 
J = 9.8 Hz), 134.8, 132.4, 130.6, 130.4, 129.2, 127.1 126.6 (d, J = 2.8 Hz), 123.9, 117.2 (d, J 
= 22.0 Hz), 68.1, 49.6, 37.3. 
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(S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-2-(4-chlorobenzyl)-3-(4-nitrobenzyl) 
isothiazolidin-4-one 1,1-dioxide (1.27.1e) 
 
According to general procedure D; 1.27.1e (48 mg, 51%) precipitated as a yellow solid. 
Mp = 156 – 159 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -24.5 (c = 0.05, CHCl3) 
HRMS calculated for C25H20ClN2O7S (M + H)
+ 527.0680; found 527.0696 (TOF MS ES+) 
FTIR (KBr film): 1708, 1604, 1519, 1367, 1230, 1171, 1040 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.13 – 7.97 (m, 2H), 7.81 – 7.64 (m, 2H), 7.52 (dd, J = 8.2, 1.9 
Hz, 1H), 7.31 – 7.15 (m, 4H), 7.11 – 7.02 (m, 2H), 6.96 (d, J = 8.2 Hz, 1H), 6.13 (s, 2H), 4.34 
(d, J = 15.0 Hz, 1H), 4.23 (d, J = 15.0 Hz, 1H), 4.00 (dd, J = 8.3, 4.9 Hz, 1H), 3.22 (dd, J = 
14.0, 8.3 Hz, 1H), 3.13 (dd, J = 14.0, 5.0 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 189.9, 154.1, 149.2, 147.3, 146.4, 143.5, 134.7, 133.7, 132.6, 
130.6, 130.4, 129.2, 124.7, 124.6, 123.9, 112.0, 109.4, 102.8, 68.1, 49.5, 37.3. 
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(S,E)-2,3-dibenzyl-5-(4-methoxybenzylidene)isothiazolidin-4-one 1,1-dioxide (1.27.1f) 
 
According to general procedure D; 1.27.1f (52 mg, 54%) precipitated as a yellow solid. 
Mp = 132 – 134 ˚C; TLC Rf = 0.4 (7:1 Hexanes/EtOAc) [α]25D = -27.4 (c = 0.1, CHCl3) 
HRMS calculated for C25H23NO4SNa (M + Na)
+ 456.1245, found 456.1249 (TOF MS ES+) 
FTIR (KBr film): 1710, 1513, 1356, 1271, 1166, 1041 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.14 – 7.97 (m, 2H), 7.77 (s, 1H), 7.36 – 7.15 (m, 8H), 7.13 – 
6.99 (m, 4H), 4.66 (d, J = 14.9 Hz, 1H), 3.99 (t, J = 6.7 Hz, 1H), 3.92 (s, 3H), 3.86 (d, J = 15.0 
Hz, 1H), 3.12 (d, J = 6.8 Hz, 2H). 
13C NMR (CDCl3, 126 MHz) δ 190.3, 165.0, 145.1, 137.1, 136.4, 134.3, 129.7, 129.1, 128.9, 
128.8, 128.3, 127.3, 125.1, 123.3, 115.2, 67.3, 55.9, 47.9, 38.0. 
(S,E)-2,3-dibenzyl-5-(4-fluorobenzylidene)isothiazolidin-4-one 1,1-dioxide (1.27.1g) 
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According to the general procedure D: flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 1.27.1g (0.44 g, 47%) as a yellow solid. 
Mp = 128 – 131 ˚C; TLC Rf = 0.4 (7:1 Hexanes/EtOAc) [α]25D = -24.8 (c = 0.1, CHCl3) 
HRMS calculated for C24H20FNO3SNa (M + Na)
+ 444.1045, found 444.1053 (TOF MS ES+) 
FTIR (KBr Film):  1718, 1543, 1271, 1166 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.19 – 8.01 (m, 2H), 7.76 (s, 1H), 7.31 (td, J = 5.8, 2.8 Hz, 3H), 
7.27 – 7.22 (m, 5H), 7.21 – 7.17 (m, 2H), 7.12 – 7.00 (m, 2H), 4.68 (d, J = 14.9 Hz, 1H), 4.02 
(dd, J = 7.7, 5.9 Hz, 1H), 3.84 (d, J = 15.0 Hz, 1H), 3.20 – 3.07 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 166.2 (d, J = 259.7 Hz), 143.6, 136.7 (d, J = 9.3 Hz), 
136.1, 134.0, 129.7, 129.1, 128.9, 128.9, 128.4, 127.8, 127.4, 126.8 (d, J = 2.9 Hz), 117.0 (d, 
J = 22.5 Hz), 67.2, 47.9, 37.9. 
(S,E)-2-benzyl-5-(4-methoxybenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-
dioxide (1.27.1h) 
 
According to general procedure D; 1.27.1h (53 mg, 57%) precipitated as a yellow solid.  
Mp = 178 – 181 ˚C; TLC Rf = 0.4 (7:1 Hexanes/EtOAc) [α]25D = -14.5 (c = 0.06, CHCl3) 
HRMS calculated for C25H22N2O6SNa (M + Na)
+ 501.1096, found 501.1096 (TOF MS ES+) 
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FTIR (KBr film): 1706, 1604, 1552, 1338, 1276, 1167, 1040 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.13 – 8.00 (m, 4H), 7.79 (s, 1H), 7.31 – 7.18 (m, 5H), 7.16 – 
7.09 (m, 2H), 7.08 – 7.00 (m, 2H), 4.38 (d, J = 14.7 Hz, 1H), 4.29 (d, J = 14.8 Hz, 1H), 4.03 
(dd, J = 8.1, 5.1 Hz, 1H), 3.92 (s, 3H), 3.22 (dd, J = 14.0, 8.1 Hz, 1H), 3.11 (dd, J = 14.0, 5.1 
Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 165.3, 147.2, 146.2, 143.7, 137.2, 134.1, 130.6, 129.2, 
129.0, 128.5, 124.4, 123.8, 123.1, 115.4, 68.0, 56.0, 50.0, 37.3. 
(S,E)-2-benzyl-5-(4-fluorobenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide 
(1.27.1i) 
 
According to general procedure D; 1.27.1i (41 mg, 45%) precipitated as a yellow solid.  
Mp = 173 – 175 ˚C; TLC Rf = 0.4 (7:1 Hexanes/EtOAc) [α]25D = -13.5 (c = 1, CHCl3) 
HRMS calculated for C24H19FN2O5SNa (M + Na)
+ 489.0996, found 489.0972 (TOF MS ES+) 
FTIR (KBr film): 1717, 1606, 1519, 1348, 1157 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.15 – 8.00 (m, 4H), 7.80 (s, 1H), 7.35 – 7.17 (m, 7H), 7.14 – 
7.05 (m, 2H), 4.39 (d, J = 14.8 Hz, 1H), 4.26 (d, J = 14.7 Hz, 1H), 4.05 (dd, J = 8.4, 5.2 Hz, 
1H), 3.24 (dd, J = 14.0, 8.3 Hz, 1H), 3.12 (dd, J = 14.0, 5.1 Hz, 1H). 
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13C NMR (CDCl3, 126 MHz) δ 190.3, 166.4 (d, J = 260.1 Hz), 147.3, 144.6, 143.4, 136.8 (d, 
J = 9.9 Hz), 133.8, 130.6, 129.1, 129.1, 128.7, 127.3 (d, J = 2.6 Hz), 126.6 (d, J = 3.4 Hz), 
123.9, 117.2 (d, J = 22.4 Hz), 68.0, 50.2, 37.2. 
(S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-2-benzyl-3-(4-nitrobenzyl)isothiazolidin-4-
one 1,1-dioxide (1.27.1j) 
 
According to general procedure D; 1.27.1j (46 mg, 48%) precipitated as a yellow solid.  
Mp = 162 – 164 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -14.2 (c = 0.9, CHCl3) 
HRMS calculated for C25H20N2O7SNa (M + Na)
+ 515.0889, found 515.0878 (TOF MS ES+) 
FTIR (KBr film): 1711, 1605, 1571, 1518, 1346, 1276, 1167, 1037 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.10 – 8.01 (m, 2H), 7.75 – 7.68 (m, 2H), 7.53 (dd, J = 8.2, 1.9 
Hz, 1H), 7.27 – 7.18 (m, 5H), 7.15 – 7.08 (m, 2H), 6.95 (d, J = 8.1 Hz, 1H), 6.12 (s, 2H), 4.38 
(d, J = 14.7 Hz, 1H), 4.28 (d, J = 14.7 Hz, 1H), 4.03 (dd, J = 8.1, 5.1 Hz, 1H), 3.22 (dd, J = 
14.0, 8.1 Hz, 1H), 3.10 (dd, J = 14.0, 5.1 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 153.9, 149.1, 147.2, 146.1, 143.6, 134.0, 133.6, 130.6, 
129.1, 129.0, 128.6, 124.9, 124.8, 123.8, 112.1, 109.3, 102.8, 68.0, 50.0, 37.3. 
 
 
109 
 
(S,E)-2-benzyl-5-((E)-3-(4-fluorophenyl)allylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 
1,1-dioxide (1.27.1k) 
 
According to general procedure D; 1.27.1k (49 mg, 51%) precipitated as a yellow solid.  
Mp = 168 – 169 ˚C; TLC Rf = 0.4 (7:1 Hexanes/EtOAc) [α]25D = -27.14 (c = 0.07, CHCl3) 
HRMS calculated for C26H21FN2O5SNa (M + Na)
+ 515.1053, found 515.1039 (TOF MS ES+) 
FTIR (KBr film): 1703, 1607, 1550, 1347, 1315, 1158 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.08 – 7.98 (m, 2H), 7.69 – 7.61 (m, 2H), 7.58 (d, J = 12.0 Hz, 
1H), 7.55 – 7.45 (m, 1H), 7.37 (d, J = 14.5 Hz, 1H), 7.30 – 7.08 (m, 9H), 4.36 (d, J = 14.7 Hz, 
1H), 4.27 (d, J = 14.8 Hz, 1H), 3.96 (dd, J = 8.0, 5.1 Hz, 1H), 3.20 (dd, J = 14.1, 8.0 Hz, 1H), 
3.08 (dd, J = 14.0, 5.1 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 190.1, 165.1 (d, J = 255.7 Hz), 152.5, 147.2, 146.4, 144.2, 
143.5, 133.9, 131.5 (d, J = 8.9 Hz), 130.6, 129.1, 129.0, 128.6, 123.8, 121.6 (d, J = 2.6 Hz), 
120.6 (d, J = 2.5 Hz), 116.7 (d, J = 22.2 Hz), 67.8, 49.8, 37.0. 
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(S,E)-3-benzyl-2-(4-fluorobenzyl)-5-(4-methoxybenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1l) 
 
According to general procedure D; 1.27.1l (44 mg, 50%) precipitated as a yellow solid. 
Mp = 142 – 146 ˚C; TLC Rf = 0.6 (4:1 Hexanes/EtOAc) [α]25D = -26.4 (c = 0.1, CHCl3) 
HRMS calculated for C25H22FNO4SNa (M + Na)
+ 474.1146, found 474.1161 (TOF MS ES+) 
FTIR: (KBr Film): 1714, 1612, 1276, 1167, 1040 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.09 – 8.04 (m, 2H), 7.78 (s, 1H), 7.33 – 7.25 (m, 3H), 7.19 
(dd, J = 7.5, 1.9 Hz, 2H), 7.07 – 7.01 (m, 2H), 6.99 (dd, J = 8.6, 5.5 Hz, 2H), 6.94 – 6.85 (m, 
2H), 4.54 (d, J = 15.0 Hz, 1H), 3.96 (dd, J = 8.4, 5.2 Hz, 1H), 3.92 (s, 3H), 3.86 (d, J = 14.9 
Hz, 1H), 3.16 – 3.09 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 162.7 (d, J = 247.1 Hz), 145.4, 137.1, 136.4, 130.8 (d, 
J = 8.2 Hz), 130.1 (d, J = 2.8 Hz), 129.7, 129.3, 128.9, 127.3, 124.9, 123.2, 115.7 (d, J = 21.8 
Hz), 115.3, 67.6, 55.9, 47.6, 38.2. 
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(S,E)-3-benzyl-2-(4-fluorobenzyl)-5-(4-fluorobenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1m) 
 
According to general procedure D; 1.27.1m (24 mg, 28%) precipitated as a yellow solid. 
Mp = 138 – 140 ˚C; TLC Rf = 0.6 (4:1 Hexanes/EtOAc) [α]25D = -24.3 (c = 0.05, CHCl3) 
HRMS calculated for C24H19F2NO3SNa (M + Na)
+ 462.0946, found 462.0925 (TOF MS ES+) 
FTIR (KBr film): 1714, 1612, 1276, 1167 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.15 – 8.04 (m, 2H), 7.78 (s, 1H), 7.31 (td, J = 5.2, 2.5 Hz, 3H), 
7.26 – 7.15 (m, 4H), 6.98 (ddd, J = 8.2, 5.3, 2.5 Hz, 2H), 6.95 – 6.86 (m, 2H), 4.55 (d, J = 14.9 
Hz, 1H), 3.99 (dd, J = 7.9, 5.9 Hz, 1H), 3.85 (d, J = 15.0 Hz, 1H), 3.21 – 3.09 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 166.3 (d, J = 259.8 Hz), 162.7 (d, J = 247.1 Hz), 143.8, 
136.7 (d, J = 9.2 Hz), 136.2, 130.8 (d, J = 8.2 Hz), 129.9 (d, J = 3.5 Hz), 129.7, 129.0, 127.7, 
127.5, 126.8 (d, J = 2.9 Hz), 117.09 (d, J = 21.8 Hz), 115.8 (d, J = 21.7 Hz), 67.6, 47.7, 38.1. 
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(S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-3-benzyl-2-(4-fluorobenzyl)isothiazolidin-4-
one 1,1-dioxide (1.27.1n) 
 
According to general procedure D; 1.27.1n (37 mg, 41%) precipitated as a yellow solid. 
Mp = 144 – 146 ˚C; TLC Rf = 0.6 (4:1 Hexanes/EtOAc) [α]25D = -31.4 (c = 0.1, CHCl3) 
HRMS calculated for C25H20FNO5SNa (M + Na)
+ 488.0944, found 488.0928 (TOF MS ES+) 
FTIR (KBr film): 1701, 1605, 1276, 1167, 1037 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.73 (d, J = 1.9 Hz, 1H), 7.71 (s, 1H), 7.53 (dd, J = 8.3, 1.9 Hz, 
1H), 7.35 – 7.27 (m, 3H), 7.22 – 7.16 (m, 2H), 7.04 – 6.89 (m, 5H), 6.11 (q, J = 1.1 Hz, 2H), 
4.54 (d, J = 15.3 Hz, 1H), 3.97 (dd, J = 8.2, 5.3 Hz, 1H), 3.87 (d, J = 15.0 Hz, 1H), 3.13 (td, J 
= 8.4, 3.2 Hz, 2H). 
13C NMR (CDCl3, 126 MHz) δ 190.2, 162.7 (d, J = 247.1 Hz), 153.6, 149.1, 145.4, 136.3, 
133.2, 130.8 (d, J = 8.2 Hz), 130.1 (d, J = 2.8 Hz), 129.7, 129.2, 128.9, 127.3, 124.9, 115.7 (d, 
J = 21.7 Hz), 112.1, 109.3, 102.7, 67.6, 47.6, 38.2. 
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(S,E)-3-benzyl-2-(4-fluorobenzyl)-5-((E)-3-(4-fluorophenyl)allylidene)isothiazolidin-4-
one 1,1-dioxide (1.27.1o) 
 
According to general procedure D; 1.27.1o (44 mg, 49%) precipitated as a yellow solid. 
Mp = 150 – 152 ˚C; TLC Rf = 0.6 (4:1 Hexanes/EtOAc) [α]25D = -22.6 (c = 0.05, CHCl3) 
HRMS calculated for C26H21F2NO3SNa (M + Na)
+ 488.1102, found 488.1097 (TOF MS ES+) 
FTIR (KBr film): 1716, 1607, 1315, 1158, 982 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.65 (ddd, J = 8.7, 5.4, 3.2 Hz, 2H), 7.57 – 7.54 (m, 1H), 7.53 
– 7.46 (m, 1H), 7.34 – 7.27 (m, 4H), 7.21 – 7.10 (m, 4H), 7.01 (ddd, J = 8.7, 5.4, 3.2 Hz, 2H), 
6.95 – 6.88 (m, 2H), 4.49 (dd, J = 18.6, 15.0 Hz, 1H), 4.04 – 3.76 (m, 2H), 3.25 – 3.03 (m, 
2H). 
13C NMR (CDCl3, 126 MHz) δ 190.1, 165.0 (d, J = 255.2 Hz), 162.7 (d, J = 247.1 Hz), 151.8, 
145.6, 143.5, 136.3, 131.4 (d, J = 8.3 Hz), 130.8 (d, J = 8.2 Hz), 130.0 (d, J = 3.6 Hz), 129.7, 
128.9, 127.4, 121.8 (d, J = 2.6 Hz), 120.7, 116.7 (d, J = 21.9 Hz), 115.8 (d, J = 21.7 Hz), 67.5, 
47.4, 37.9. 
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(S,E)-2-(4-fluorobenzyl)-5-(4-methoxybenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-
one 1,1-dioxide (1.27.1p) 
 
According to general procedure D; 1.27.1p (52 mg, 57%) precipitated as a yellow solid.  
Mp = 168 – 171 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -29.4 (c = 0.05, CHCl3) 
HRMS calculated for C25H21FN2O6SNa (M + Na)
+ 519.1002, found 519.1017 (TOF MS ES+) 
FTIR (KBr film): 1709, 1606, 1512, 1347, 1290, 1166, 1054 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.13 – 8.08 (m, 2H), 8.07 – 8.02 (m, 2H), 7.79 (s, 1H), 7.26 (m, 
2H), 7.15 – 7.08 (m, 2H), 7.07 – 7.02 (m, 2H), 6.97 – 6.89 (m, 2H), 4.40 (d, J = 14.9 Hz, 1H), 
4.21 (d, J = 14.9 Hz, 1H), 4.01 (dd, J = 8.1, 5.0 Hz, 1H), 3.93 (s, 3H), 3.24 (dd, J = 14.1, 8.1 
Hz, 1H), 3.13 (dd, J = 14.1, 5.0 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 189.9, 165.4, 162.8 (d, J = 248.4 Hz), 147.3, 146.3, 143.6, 
137.3, 130.9 (d, J = 8.5 Hz), 130.7, 129.9 (d, J = 3.5 Hz), 124.3, 123.8, 123.1, 116.0 (d, J = 
21.7 Hz), 115.4, 67.8, 56.0, 49.1, 37.3. 
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(S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-2-(4-fluorobenzyl)-3-(4-nitrobenzyl) 
isothiazolidin-4-one 1,1-dioxide (1.27.1q) 
 
According to general procedure D; 1.27.1q (55 mg, 58%) precipitated as a yellow solid.  
Mp = 168 – 172 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -22.4 (c = 0.1, CHCl3) 
HRMS calculated for C25H19FN2O7SNa (M + Na)
+ 533.0795, found 533.0810 (TOF MS ES+) 
FTIR (KBr film): 1710, 1604, 1510, 1346, 1277, 1157, 1038 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.17 – 8.05 (m, 2H), 7.72 (s, 1H), 7.70 (d, J = 1.9 Hz, 1H), 7.52 
(dd, J = 8.4, 1.9 Hz, 1H), 7.27 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 1.9 Hz, 1H), 7.10 (ddd, J = 8.4, 
5.3, 2.6 Hz, 2H), 7.01 – 6.83 (m, 3H), 6.13 (s, 2H), 4.40 (d, J = 15.0 Hz, 1H), 4.20 (d, J = 14.9 
Hz, 1H), 4.01 (dd, J = 8.1, 5.0 Hz, 1H), 3.23 (dd, J = 14.0, 8.1 Hz, 1H), 3.13 (dd, J = 14.0, 5.0 
Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 189.9, 162.8 (d, J = 248.2 Hz), 154.0, 149.2, 147.3, 146.3, 
143.5, 133.7, 130.9 (d, J = 8.2 Hz), 130.7, 129.9 (d, J = 2.9 Hz), 124.7, 124.7, 123.9, 116.0 (d, 
J = 21.8 Hz), 112.1, 109.4, 102.8, 67.8, 49.1, 37.3. 
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(S,E)-2-(4-fluorobenzyl)-5-((E)-3-(4-fluorophenyl)allylidene)-3-(4-nitrobenzyl) 
isothiazolidin-4-one 1,1-dioxide (1.27.1r) 
 
According to general procedure D; 1.27.1r (52 mg, 55%) precipitated as a yellow solid.  
Mp = 162 – 165 ˚C; TLC Rf = 0.3 (7:1 Hexanes/EtOAc) [α]25D = -26 .2 (c = 0.01, CHCl3) 
HRMS calculated for C26H20F2N2O5SNa (M + Na)
+ 533.0959, found 533.0951 (TOF MS ES+) 
FTIR (KBr film): 1706, 1606, 1509, 1347, 1313, 1158 cm-1 
1H NMR (CDCl3, 400 MHz) δ 8.14 – 8.06 (m, 2H), 7.70 – 7.62 (m, 2H), 7.58 (d, J = 11.9 Hz, 
1H), 7.54 – 7.44 (m, 1H), 7.38 (d, J = 14.6 Hz, 1H), 7.26 – 7.22 (m, 2H), 7.19 – 7.07 (m, 4H), 
6.98 – 6.90 (m, 2H), 4.38 (d, J = 14.9 Hz, 1H), 4.19 (d, J = 14.9 Hz, 1H), 3.94 (dd, J = 8.0, 5.0 
Hz, 1H), 3.21 (dd, J = 14.1, 8.0 Hz, 1H), 3.11 (dd, J = 14.1, 5.1 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 189.7, 165.2 (d, J = 255.8 Hz), 162.8 (d, J = 248.0 Hz), 152.8, 
147.3, 146.6, 144.4, 143.5, 131.6 (d, J = 9.0 Hz), 130.9 (d, J = 8.2 Hz), 130.7, 129.8 (d, J = 
3.6 Hz), 127.3, 123.8, 120.6 (d, J = 2.6 Hz), 116.8 (d, J = 22.5 Hz), 116.0 (d, J = 21.7 Hz), 
67.6, 48.9, 37.0. 
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Methyl (S)-2-amino-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate (2.7.3) 
 
According to general procedure E; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 2.7.3 (2.86 g, 67%) as a pale-yellow oil. 
TLC Rf = 0.5 (2% Methanol in EtOAc) [α]25D = -39.4 (c = 0.1, CHCl3) 
HRMS calculated for C16H28NO3Si (M + H)
+ 310.1838, found 310.1851 (TOF MS ES+) 
FTIR (neat): 3210, 1742, 1675, 920 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.02 (d, J = 8.5 Hz, 2H), 6.76 (d, J = 8.4 Hz, 2H), 3.76 – 3.61 
(m, 4H), 2.99 (dd, J = 13.6, 5.3 Hz, 1H), 2.80 (dd, J = 13.6, 7.7 Hz, 1H), 1.46 (s, 2H), 0.96 (s, 
9H), 0.17 (s, 6H). 
13C NMR (CDCl3, 126 MHz) δ 175.7, 154.7, 130.3, 129.9, 120.2, 56.1, 52.0, 40.5, 25.8, 18.3, 
-4.3. 
Methyl O-(tert-butyldimethylsilyl)-L-serinate (2.10.2) 
 
According to general procedure E; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 2.10.2 (3.6 g 80%) as an off-white oil. 
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TLC Rf = 0.5 (2% Methanol in EtOAc) [α]25D = -34.4 (c = 0.5, CHCl3) 
HRMS calculated for C10H24NO3Si (M + H)
+ 234.1525, found 234.1535 (TOF MS ES+) 
FTIR (neat): 3213, 1751, 1679, 882 cm-1 
1H NMR (CDCl3, 400 MHz) δ 3.86 (ddd, J = 9.7, 4.5, 1.3 Hz, 1H), 3.76 (ddd, J = 9.7, 3.8, 1.3 
Hz, 1H), 3.67 (d, J = 1.3 Hz, 3H), 3.47 (td, J = 4.1, 1.4 Hz, 1H), 1.64 (s, 2H), 0.82 (d, J = 1.3 
Hz, 9H), -0.01 (dd, J = 4.6, 1.3 Hz, 6H). 
13C NMR (CDCl3, 126 MHz) δ 174.6, 65.5, 56.6, 52.0, 25.8, 18.2, -5.5 (d, J = 15.0 Hz). 
Methyl (S)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(methylsulfonamido)propanoate 
(2.7.4) 
 
According to general procedure A; flash chromatography (5% EtOAc in Hexane to 20% 
EtOAc in Hexane) provided 2.7.4 (3.48 g, 97%) as an off-white solid. 
Mp = 121 – 124 ˚C; TLC Rf = 0.4 (1:1 Hexanes/EtOAc) [α]25D = -14.15 (c =0.03, CHCl3) 
HRMS calculated for C17H29NO5SSiNa (M + Na)
+ 410.1433, found 410.1443 (TOF MS ES+) 
FTIR (KBr film): 1753, 1657, 1367, 1152, 927 cm-1 
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1H NMR (CDCl3, 400 MHz) δ 7.10 – 6.97 (m, 2H), 6.86 – 6.73 (m, 2H), 4.84 (d, J = 9.2 Hz, 
1H), 4.34 (ddd, J = 9.2, 7.4, 5.1 Hz, 1H), 3.77 (s, 3H), 3.08 (dd, J = 13.9, 5.1 Hz, 1H), 2.94 
(dd, J = 13.9, 7.4 Hz, 1H), 2.68 (s, 3H), 0.97 (s, 9H), 0.17 (s, 6H). 
13C NMR (CDCl3, 126 MHz) δ 172.1, 155.3, 130.7, 128.1, 120.6, 57.4, 52.8, 41.5, 38.9, 25.8, 
18.3, -4.3. 
Methyl O-(tert-butyldimethylsilyl)-N-(methylsulfonyl)-L-serinate (2.10.3) 
 
According to general procedure A; flash chromatography (5% EtOAc in Hexane to 20% 
EtOAc in Hexane) provided 2.10.3 (1.28 g, 91%) as a pale-yellow solid.  
Mp = 107 – 109 ˚C; TLC Rf = 0.5 (1:1 Hexanes/EtOAc) [α]25D = -21.3 (c = 0.5, CHCl3) 
HRMS calculated for C11H25NO5SSiNa (M + Na)
+ 334.1120, found 334.1128 (TOF MS ES+) 
FTIR (Kbr film): 1750, 1322, 1126, 838 cm-1 
1H NMR (CDCl3, 400 MHz) δ 5.35 (d, J = 9.2 Hz, 1H), 4.17 (dt, J = 9.2, 3.2 Hz, 1H), 4.01 
(dd, J = 10.0, 3.3 Hz, 1H), 3.82 (dd, J = 10.0, 3.2 Hz, 1H), 3.72 (s, 3H), 2.95 (s, 3H), 0.80 (s, 
9H), -0.01 (d, J = 6.4 Hz, 5H). 
13C NMR (CDCl3, 126 MHz) δ 170.8, 64.8, 57.9, 52.6, 41.8, 25.6, 18.1, -5.6 (d, J = 26.2 Hz). 
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Methyl (S)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(N-(2-chlorobenzyl)methyl 
sulfonamido)propanoate (2.8.1a) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 20% EtOAc 
in Hexane) provided 2.8.1a (3.36 g, 85%) as an off-white solid. 
Mp = 126 – 128 ˚C; TLC Rf = 0.4 (4:1 Hexanes/EtOAc) [α]25D = -26.6 (c = 0.1, CHCl3) 
HRMS calculated for C24H34ClNO5SSiNa (M + Na)
+ 534.1508, found 534.1532 (TOF MS 
ES+) 
FTIR (KBr film): 1756, 1643, 1360, 1142, 934 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.57 – 7.48 (m, 1H), 7.36 – 7.29 (m, 1H), 7.23 – 7.14 (m, 2H), 
7.02 – 6.93 (m, 2H), 6.77 – 6.68 (m, 2H), 4.74 (dd, J = 8.3, 7.2 Hz, 1H), 4.68 – 4.53 (m, 2H), 
3.61 (s, 3H), 3.12 (dd, J = 14.5, 7.2 Hz, 1H), 2.96 (dd, J = 14.4, 8.3 Hz, 1H), 2.79 (s, 3H), 0.97 
(s, 9H), 0.17 (s, 6H). 
13C NMR (CDCl3, 126 MHz) δ 171.1, 154.8, 134.3, 132.9, 130.5, 130.2, 129.4, 129.4, 129.0, 
127.1, 120.3, 62.1, 52.4, 46.9, 39.7, 36.0, 25.8, 18.3, -4.3. 
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Methyl (S)-2-(N-benzylmethylsulfonamido)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl) 
propanoate (2.8.1b) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.8.1b (2.48 g, 93%) as an off-white solid. 
Mp = 102 – 104 ˚C; TLC Rf = 0.4 (2:1 Hexanes/EtOAc) [α]25D = -24.5 (c = 0.1, CHCl3) 
HRMS calculated for C24H35NO5SSiNa (M + Na)
+ 500.1903, found 500.1893 (TOF MS ES+) 
FTIR (KBr film): 1734, 1607, 1326, 1143, 914 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.45 – 7.18 (m, 5H), 6.99 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 8.5 
Hz, 2H), 4.68 (dd, J = 8.4, 7.0 Hz, 1H), 4.50 (d, J = 15.6 Hz, 1H), 4.29 (d, J = 15.6 Hz, 1H), 
3.58 (s, 3H), 3.17 (dd, J = 14.4, 7.0 Hz, 1H), 2.95 (dd, J = 14.4, 8.4 Hz, 1H), 2.68 (s, 3H), 0.98 
(s, 9H), 0.18 (s, 6H). 
13C NMR (CDCl3, 126 MHz) δ 171.1, 154.6, 136.3, 130.3, 129.7, 128.8, 128.6, 128.0, 120.3, 
61.9, 52.3, 49.8, 40.4, 36.2, 25.8, 18.3, -4.4. 
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Methyl (S)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(N-(4-fluorobenzyl)methyl 
sulfonamido)propanoate (2.8.1c) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.8.1c (3.48 g, 91%) as an off-white solid. 
Mp = 112 – 114 ˚C; TLC Rf = 0.4 (2:1 Hexanes/EtOAc) [α]25D = -34 (c = 0.5, CHCl3) 
HRMS calculated for C24H34FNO5SSiNa (M + Na)
+ 518.1809, found 518.1820 (TOF MS ES+) 
FTIR (KBr film): 1734, 1606, 1327, 1142, 911 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.34 – 7.27 (m, 2H), 6.98 (ddd, J = 8.7, 5.6, 2.7 Hz, 4H), 6.79 
– 6.69 (m, 2H), 4.70 (dd, J = 8.6, 6.9 Hz, 1H), 4.46 (d, J = 15.7 Hz, 1H), 4.27 (d, J = 15.7 Hz, 
1H), 3.60 (s, 3H), 3.16 (dd, J = 14.5, 6.9 Hz, 1H), 2.91 (dd, J = 14.4, 8.6 Hz, 1H), 2.68 (s, 3H), 
0.97 (s, 9H), 0.17 (s, 6H). 
13C NMR (CDCl3, 126 MHz) δ 171.2, 162.6 (d, J = 246.2 Hz), 154.8, 132.2 (d, J = 2.9 Hz), 
130.6 (d, J = 8.2 Hz), 130.2, 129.5, 120.4, 115.5 (d, J = 21.0 Hz), 61.8, 52.4, 49.1, 40.34, 36.1, 
25.8, 18.4, -4.3. 
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Methyl O-(tert-butyldimethylsilyl)-N-(2-chlorobenzyl)-N-(methylsulfonyl)-L-serinate 
(2.10.4a) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.10.4a (2.46 g, 88%) as an off-white solid. 
Mp = 104 – 107 ˚C; TLC Rf = 0.4 (4:1 Hexanes/EtOAc) [α]25D = -21.34 (c = 0.5, CHCl3) 
HRMS calculated for C18H30ClNO5SSiNa (M + Na)
+ 458.1200, found 458.1194 (TOF MS 
ES+) 
FTIR (KBr film): 1753, 1340, 1143, 913 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.73 – 7.68 (m, 1H), 7.32 – 7.23 (m, 2H), 7.17 (td, J = 7.6, 1.7 
Hz, 1H), 4.78 – 4.64 (m, 3H), 4.13 (dd, J = 10.9, 6.0 Hz, 1H), 3.98 (dd, J = 10.9, 3.0 Hz, 1H), 
3.74 (s, 3H), 3.00 (s, 3H), 0.73 (s, 9H), -0.11 (s, 3H), -0.23 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 170.1, 135.9, 132.4, 129.2, 128.8, 128.3, 126.8, 63.1, 62.4, 
52.5, 48.8, 39.0, 25.7, 18.2, -5.9 (d, J = 5.1 Hz). 
Methyl N-benzyl-O-(tert-butyldimethylsilyl)-N-(methylsulfonyl)-L-serinate (2.10.4b) 
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According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.10.4b (1.21 g, 91%) as an off-white solid.  
Mp = 107 – 109 ˚C; TLC Rf = 0.4 (4:1 Hexanes/EtOAc) [α]25D = -34.4 (c = 0.1, CHCl3) 
HRMS calculated for C18H31NO5SSiNa (M + Na)
+ 424.1590, found 424.1585 (TOF MS ES+) 
FTIR (KBr film): 1749, 1311, 1147, 964 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.44 – 7.39 (m, 2H), 7.31 (tt, J = 6.5, 1.0 Hz, 2H), 7.28 – 7.22 
(m, 1H), 4.66 – 4.60 (m, 2H), 4.55 (d, J = 16.1 Hz, 1H), 4.04 (dd, J = 11.0, 7.1 Hz, 1H), 3.97 
(dd, J = 10.9, 4.2 Hz, 1H), 3.67 (s, 3H), 2.88 (s, 3H), 0.83 (s, 9H), -0.02 (s, 3H), -0.08 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 170.2, 137.3, 128.5, 128.2, 127.6, 62.4, 62.0, 52.3, 50.4, 40.3, 
25.9, 18.3, -5.7 (d, J = 13.7 Hz). 
Methyl O-(tert-butyldimethylsilyl)-N-(4-fluorobenzyl)-N-(methylsulfonyl)-L-serinate 
(2.10.4c) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.10.4c (2.49 g, 92%) as an off-white solid. 
Mp = 106 – 107 ˚C; TLC Rf = 0.4 (4:1 Hexanes/EtOAc) [α]25D = -28.4 (c = 0.5, CHCl3) 
HRMS calculated for C18H30FNO5SSiNa (M + Na)
+ 442.1496, found 442.1498 (TOF MS ES+) 
FTIR (KBr film): 1754, 1325, 1141, 916 cm-1 
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1H NMR (CDCl3, 400 MHz) δ 7.43 – 7.37 (m, 2H), 7.03 – 6.96 (m, 2H), 4.66 – 4.57 (m, 2H), 
4.51 (d, J = 15.7 Hz, 1H), 4.03 (dd, J = 11.0, 7.0 Hz, 1H), 3.95 (dd, J = 11.0, 4.0 Hz, 1H), 3.68 
(s, 3H), 2.87 (s, 3H), 0.82 (s, 9H), -0.02 (s, 3H), -0.07 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 170.1, 162.4 (d, J = 246.0 Hz), 133.3 (d, J = 2.8 Hz), 129.8 (d, 
J = 7.7 Hz), 115.3 (d, J = 21.1 Hz), 62.5, 62.0, 52.4, 49.7, 40.1, 25.8, 18.2, -5.7 (d, J = 15.4 
Hz). 
Methyl N-(2-chlorobenzyl)-N-(methylsulfonyl)-L-tyrosinate (2.9.1a) 
 
According to general procedure F; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 2.9.1a (2.37 g, 87%) as an off-white solid. 
Mp = 136 – 138 ˚C; TLC Rf = 0.5 (2:1 Hexanes/EtOAc) [α]25D = -36.2 (c = 0.05, CHCl3) 
HRMS calculated for C18H20ClNO5SNa (M + Na)
+ 420.0648, found 420.0660 (TOF MS ES+) 
FTIR (KBr film): 3356, 1718, 1605, 1346, 1154 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.48 (dd, J = 7.4, 2.1 Hz, 1H), 7.36 – 7.29 (m, 1H), 7.23 – 7.12 
(m, 2H), 7.01 – 6.89 (m, 2H), 6.74 – 6.65 (m, 2H), 5.19 (s, 1H), 4.73 (dd, J = 8.4, 7.0 Hz, 1H), 
4.61 (d, J = 16.9 Hz, 1H), 4.56 (d, J = 16.9 Hz, 1H), 3.63 (s, 3H), 3.13 (dd, J = 14.5, 7.0 Hz, 
1H), 2.95 (dd, J = 14.5, 8.4 Hz, 1H), 2.83 (s, 3H). 
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13C NMR (CDCl3, 126 MHz) δ 171.1, 154.9, 134.0, 132.9, 130.5, 130.3, 129.4, 129.1, 128.4, 
127.1, 115.6, 62.3, 52.5, 47.0, 39.8, 35.9. 
Methyl N-benzyl-N-(methylsulfonyl)-L-tyrosinate (2.9.1b) 
 
According to general procedure F; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 2.9.1b (1.66 g, 91%) as an off-white solid. 
Mp = 142 – 144 ˚C; TLC Rf = 0.6 (1:1 Hexanes/EtOAc) [α]25D = - 34.6 (c = 0.05, CHCl3) 
HRMS calculated for C18H21NO5SNa (M + Na)
+ 386.1033, found 386.1049 (TOF MS ES+) 
FTIR (KBr film): 3364, 1712, 1615, 1336, 1150 cm-1 
1H NMR ((CDCl3, 400 MHz) δ 7.38 – 7.22 (m, 5H), 7.03 – 6.92 (m, 2H), 6.79 – 6.65 (m, 2H), 
5.42 (s, 1H), 4.66 (dd, J = 8.3, 7.0 Hz, 1H), 4.48 (d, J = 15.6 Hz, 1H), 4.28 (d, J = 15.6 Hz, 
1H), 3.61 (s, 3H), 3.17 (dd, J = 14.4, 7.0 Hz, 1H), 2.93 (dd, J = 14.4, 8.3 Hz, 1H), 2.74 (s, 3H). 
13C NMR ((CDCl3, 126 MHz) δ 171.2, 154.8, 136.2, 130.5, 128.9, 128.9, 128.7, 128.1, 115.6, 
62.1, 52.5, 50.0, 40.5, 36.1. 
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Methyl N-(4-fluorobenzyl)-N-(methylsulfonyl)-L-tyrosinate (2.9.1c) 
 
According to general procedure F; flash chromatography (5% EtOAc in Hexane to 25% EtOAc 
in Hexane) provided 2.9.1c (2.64 g, 99%) as an off-white solid.  
Mp = 138 – 140 ˚C; TLC Rf = 0.5 (1:1 Hexanes/EtOAc) [α]25D = -22.8 (c = 0.05, CHCl3) 
HRMS calculated for C18H20FNO5SNa (M + Na)
+ 404.0938, found 404.0948 (TOF MS ES+) 
FTIR (KBr film): 3404, 1713, 1614, 1331, 1149 cm-1 
1H NMR ((CDCl3, 400 MHz) δ 7.32 – 7.24 (m, 2H), 7.01 – 6.91 (m, 4H), 6.75 – 6.68 (m, 2H), 
5.45 (s, 1H), 4.67 (dd, J = 8.6, 6.8 Hz, 1H), 4.45 (d, J = 15.7 Hz, 1H), 4.25 (d, J = 15.7 Hz, 
1H), 3.63 (s, 3H), 3.15 (dd, J = 14.4, 6.8 Hz, 1H), 2.90 (dd, J = 14.5, 8.6 Hz, 1H), 2.74 (s, 3H). 
13C NMR ((CDCl3, 126 MHz) δ 171.2, 162.6 (d, J = 246.3 Hz), 154.9, 132.0 (d, J = 2.8 Hz), 
130.6 (d, J = 8.2 Hz), 130.4, 128.6, 115.6, 115.5 (d, J = 19.9 Hz), 62.0, 52.6, 49.2, 40.4, 36.1. 
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Methyl (S)-3-(4-(allyloxy)phenyl)-2-(N-(2-chlorobenzyl)methylsulfonamido)propanoate 
(2.9.2a) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.9.2a (2.13 g, 89%) as an off-white solid.  
Mp = 144 – 146 ˚C; TLC Rf = 0.3 (4:1 Hexanes/EtOAc) [α]25D = -21.3 (c = 0.05, CHCl3) 
HRMS calculated for C21H24ClNO5SNa (M + Na)
+ 460.0956, found 460.0970 (TOF MS ES+) 
FTIR (KBr film): 1719, 1616, 1336, 1141, 891 cm-1 
1H NMR ((CDCl3, 400 MHz) δ 7.52 – 7.47 (m, 1H), 7.35 – 7.30 (m, 1H), 7.23 – 7.13 (m, 2H), 
7.04 – 6.97 (m, 2H), 6.82 – 6.75 (m, 2H), 6.03 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.39 (dq, J = 
17.3, 1.7 Hz, 1H), 5.27 (dq, J = 10.5, 1.4 Hz, 1H), 4.73 (dd, J = 8.2, 7.2 Hz, 1H), 4.59 (d, J = 
4.0 Hz, 2H), 4.49 (dt, J = 5.3, 1.6 Hz, 2H), 3.62 (s, 3H), 3.14 (dd, J = 14.4, 7.2 Hz, 1H), 2.96 
(dd, J = 14.5, 8.2 Hz, 1H), 2.82 (s, 3H). 
13C NMR ((CDCl3, 126 MHz) δ 171.0, 157.6, 134.2, 133.3, 132.8, 130.4, 130.1, 129.3, 128.9, 
128.8, 127.0, 117.6, 114.8, 68.8, 62.1, 52.4, 46.9, 39.6, 35.9. 
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Methyl (S)-3-(4-(allyloxy)phenyl)-2-(N-benzylmethylsulfonamido)propanoate (2.9.2b) 
 
According to general procedure B; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.9.2b (1.85 g, 90%) as an off-white solid.  
Mp = 138 – 141 ˚C; TLC Rf = 0.3 (4:1 Hexanes/EtOAc) [α]25D = -32.4 (c = 0.05, CHCl3) 
HRMS calculated for C21H25NO5SNa (M + Na)
+ 426.1351, found 426.1353 (TOF MS ES+) 
FTIR (KBr film): 1744, 1626, 1513, 1321, 1141, 804 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.36 – 7.23 (m, 5H), 7.06 – 6.98 (m, 2H), 6.86 – 6.76 (m, 2H), 
6.04 (ddt, J = 17.2, 10.5, 5.3 Hz, 1H), 5.40 (dq, J = 17.3, 1.6 Hz, 1H), 5.27 (dq, J = 10.5, 1.4 
Hz, 1H), 4.67 (dd, J = 8.2, 7.1 Hz, 1H), 4.53 – 4.44 (m, 3H), 4.29 (d, J = 15.6 Hz, 1H), 3.60 
(s, 3H), 3.18 (dd, J = 14.3, 7.1 Hz, 1H), 2.94 (dd, J = 14.4, 8.2 Hz, 1H), 2.72 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 171.0, 157.5, 136.3, 133.3, 130.3, 129.1, 128.8, 128.5, 128.0, 
117.6, 114.8, 68.8, 61.9, 52.3, 49.9, 40.3, 36.1. 
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Methyl (S)-3-(4-(allyloxy)phenyl)-2-(N-(4-fluorobenzyl)methylsulfonamido)propanoate 
(2.9.2c) 
 
According to general procedure b; flash chromatography (5% EtOAc in Hexane to 15% EtOAc 
in Hexane) provided 2.9.2c (2.60 g, 87%) as an off-white solid. 
Mp = 144 – 146 ˚C; TLC Rf = 0.3 (4:1 Hexanes/EtOAc) [α]25D = -24.4 (c = 0.05, CHCl3) 
HRMS calculated for C21H24NO5SNa (M + Na)
+ 444.1257, found 444.1277 (TOF MS ES+) 
FTIR (KBr film): 1742, 1611, 1514, 1321, 1116, 824 cm-1 
1H NMR (400 MHz, Chloroform-d) δ 7.32 – 7.24 (m, 2H), 7.05 – 6.91 (m, 4H), 6.83 – 6.76 
(m, 2H), 6.03 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.39 (dq, J = 17.3, 1.6 Hz, 1H), 5.27 (dq, J = 
10.5, 1.4 Hz, 1H), 4.68 (dd, J = 8.5, 6.9 Hz, 1H), 4.49 (dt, J = 5.3, 1.6 Hz, 2H), 4.44 (d, J = 
15.7 Hz, 1H), 4.26 (d, J = 15.7 Hz, 1H), 3.61 (s, 3H), 3.16 (dd, J = 14.4, 6.9 Hz, 1H), 2.90 (dd, 
J = 14.4, 8.5 Hz, 1H), 2.71 (s, 3H). 
13C NMR (CDCl3, 126 MHz) δ 171.0, 162.4 (d, J = 246.3 Hz), 157.6, 133.3, 132.1 (d, J = 3.4 
Hz), 130.5 (d, J = 8.0 Hz), 130.2, 128.9, 117.7, 115.3 (d, J = 21.1 Hz), 114.8, 68.8, 61.8, 52.4, 
49.1, 40.2, 36.0. 
 
 
131 
 
(S)-3-(4-(allyloxy)benzyl)-2-(2-chlorobenzyl)isothiazolidin-4-one 1,1-dioxide (2.9.3a) 
 
According to general procedure C; flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 2.9.3a (0.90 g, 51%) as a pale-orange solid. 
Mp = 152 – 154 ˚C; TLC Rf = 0.3 (3:1 Hexanes/EtOAc) [α]25D = -18.2 (c = 0.01, CHCl3) 
HRMS calculated for C20H20ClNO4SNa (M + Na)
+ 428.0700, found 428.0718 (TOF MS ES+) 
FTIR (KBr film): 1763, 1611, 1512, 1323, 1138, 826 cm-1 
1H NMR ((CDCl3, 400 MHz) δ 7.35 – 7.31 (m, 1H), 7.30 – 7.19 (m, 3H), 7.02 – 6.93 (m, 2H), 
6.82 – 6.75 (m, 2H), 6.05 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.41 (dq, J = 17.3, 1.6 Hz, 1H), 
5.29 (dq, J = 10.5, 1.4 Hz, 1H), 4.60 (d, J = 15.3 Hz, 1H), 4.53 – 4.44 (m, 3H), 3.98 (td, J = 
6.1, 1.4 Hz, 1H), 3.75 (d, J = 16.6 Hz, 1H), 3.53 (dd, J = 16.6, 1.4 Hz, 1H), 3.04 (d, J = 6.1 
Hz, 2H). 
13C NMR ((CDCl3, 126 MHz) δ 198.5, 158.0, 134.1, 133.3, 132.1, 131.6, 130.8, 130.0, 129.9, 
127.5, 127.2, 117.9, 115.0, 70.5, 68.9, 55.6, 45.7, 36.4. 
 
 
 
 
132 
 
(S)-3-(4-(allyloxy)benzyl)-2-benzylisothiazolidin-4-one 1,1-dioxide (2.9.3b) 
 
According to general procedure C; flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 2.9.3b (0.68 g, 47%) as a pale-orange solid. 
Mp = 148 – 150 ˚C; TLC Rf = 0.3 (3:1 Hexanes/EtOAc) [α]25D = -28.2 (c = 0.01, CHCl3) 
HRMS calculated for C20H21NO4SNa (M + Na)
+ 394.1089, found 394.1095 (TOF MS ES+) 
FTIR (KBr film): 1753, 1609, 1512, 1331, 1136, 821 cm-1 
1H NMR (CDCl3, 400 MHz) δ 7.34 – 7.29 (m, 3H), 7.17 (dd, J = 6.6, 2.9 Hz, 2H), 7.06 – 7.01 
(m, 2H), 6.89 – 6.82 (m, 2H), 6.06 (ddt, J = 17.3, 10.6, 5.3 Hz, 1H), 5.42 (dq, J = 17.2, 1.6 Hz, 
1H), 5.30 (dq, J = 10.5, 1.4 Hz, 1H), 4.71 (d, J = 15.0 Hz, 1H), 4.54 (dt, J = 5.3, 1.6 Hz, 2H), 
3.90 (ddd, J = 7.6, 4.7, 1.4 Hz, 1H), 3.85 (d, J = 15.1 Hz, 1H), 3.65 (d, J = 16.5 Hz, 1H), 3.52 
(dd, J = 16.5, 1.4 Hz, 1H), 3.09 – 2.94 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 198.3, 157.9, 133.9, 133.2, 130.6, 129.2, 129.0, 128.6, 127.5, 
117.9, 115.1, 69.0, 68.9, 56.0, 47.9, 36.1. 
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(S)-3-(4-(allyloxy)benzyl)-2-(4-fluorobenzyl)isothiazolidin-4-one 1,1-dioxide (2.9.3c) 
 
According to general procedure C; flash chromatography (100% Hexane to 10% EtOAc in 
Hexane) provided 2.9.3c (0.70 g, 51%) as a pale-orange solid. 
Mp = 154 – 156 ˚C; TLC Rf = 0.4 (3:1 Hexanes/EtOAc) [α]25D = -22.8 (c = 0.05, CHCl3) 
HRMS calculated for C20H20FNO4SNa (M + Na)
+ 412.0995, found 412.1014 (TOF MS ES+) 
FTIR (KBr film): 1753, 1609, 1512, 1331, 1136, 821 cm-1 
1H NMR (CHCl3, 400 MHz) δ 7.15 – 7.09 (m, 2H), 7.06 – 6.95 (m, 4H), 6.89 – 6.81 (m, 2H), 
6.06 (ddt, J = 17.3, 10.6, 5.3 Hz, 1H), 5.43 (dq, J = 17.2, 1.6 Hz, 1H), 5.31 (dq, J = 10.5, 1.4 
Hz, 1H), 4.61 (d, J = 15.1 Hz, 1H), 4.53 (dt, J = 5.4, 1.5 Hz, 2H), 3.91 – 3.86 (m, 2H), 3.66 (d, 
J = 16.6 Hz, 1H), 3.54 (dd, J = 16.6, 1.3 Hz, 1H), 3.10 – 2.96 (m, 2H). 
13C NMR (CHCl3, 126 MHz) δ 198.3, 162.8 (d, J = 247.9 Hz), 158.1, 133.2, 131.1 (d, J = 8.2 
Hz), 130.7, 129.9 (d, J = 3.6 Hz), 127.6, 118.0, 116.0 (d, J = 21.7 Hz), 115.2, 69.3, 69.0, 56.0, 
47.4, 36.3. 
3-(but-3-en-1-yloxy)benzaldehyde (2.11.5) 
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According to general procedure B; flash chromatography (100% Hexane to 2% EtOAc in 
Hexane) provided 2.11.5 (1.90 g, 88%) as a pale-yellow liquid. 
TLC Rf = 0.7 (7:1 Hexanes/EtOAc); FTIR (neat): 1699, 1599, 1386, 1263, 1040 cm-1 
HRMS calculated for C11H12O2Na (M + Na)
+ 199.0735, found 199.0749 (TOF MS ES+) 
1H NMR (CDCl3, 400 MHz) δ 9.97 (s, 1H), 7.50 – 7.35 (m, 3H), 7.18 (dt, J = 6.4, 2.7 Hz, 1H), 
5.91 (ddt, J = 17.1, 10.3, 6.7 Hz, 1H), 5.18 (dq, J = 17.2, 1.6 Hz, 1H), 5.12 (dq, J = 10.2, 1.3 
Hz, 1H), 4.08 (t, J = 6.7 Hz, 2H), 2.57 (qt, J = 6.7, 1.4 Hz, 2H). 
13C NMR ((CDCl3, 126 MHz) δ 192.3, 159.6, 137.9, 134.3, 130.2, 123.6, 122.1, 117.4, 113.0, 
67.6, 33.6. 
3-(pent-4-en-1-yloxy)benzaldehyde (2.11.4) 
 
According to general procedure B; flash chromatography (100% Hexane to 2% EtOAc in 
Hexane) provided 2.11.4 (2.18 g, 93%) as a pale-yellow liquid. 
TLC Rf = 0.6 (7:1 Hexanes/EtOAc) FTIR (neat): 1694, 1603, 1382, 1268, 1047 cm-1 
HRMS calculated for C12H14O2Na (M + Na)
+ 213.0891 found 213.0907 (TOF MS ES+) 
1H NMR (CDCl3, 400 MHz) δ 9.96 (s, 1H), 7.47 – 7.33 (m, 3H), 7.16 (dt, J = 5.8, 2.7 Hz, 1H), 
5.84 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.06 (dq, J = 17.1, 1.7 Hz, 1H), 5.00 (ddt, J = 10.2, 2.2, 
1.3 Hz, 1H), 4.01 (t, J = 6.4 Hz, 2H), 2.34 – 2.15 (m, 2H), 2.01 – 1.82 (m, 2H). 
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13C NMR (CDCl3, 126 MHz) δ 192.3, 159.8, 137.9, 137.7, 130.1, 123.5, 122.0, 115.5, 112.9, 
67.5, 30.1, 28.4. 
3-(hex-5-en-1-yloxy)benzaldehyde (2.11.6) 
 
According to general procedure B; flash chromatography (100% Hexane to 2% EtOAc in 
Hexane) provided 2.11.6 (2.28 g, 91%) as a pale-yellow liquid. 
TLC Rf = 0.6 (7:1 Hexanes/EtOAc) FTIR (neat): 1707, 1605, 1378, 1266, 1042 cm-1 
HRMS calculated for C13H16O2Na (M + Na)
+ 227.1048, found 227.1036 (TOF MS ES+) 
1H NMR (CDCl3, 400 MHz) δ 9.97 (s, 1H), 7.52 – 7.32 (m, 3H), 7.22 – 7.11 (m, 1H), 5.83 
(ddt, J = 16.9, 10.1, 6.6 Hz, 1H), 5.04 (dq, J = 17.1, 1.7 Hz, 1H), 4.98 (ddt, J = 10.2, 2.2, 1.2 
Hz, 1H), 4.02 (t, J = 6.5 Hz, 2H), 2.18 – 2.09 (m, 2H), 1.87 – 1.78 (m, 2H), 1.58 (tt, J = 9.6, 
6.4 Hz, 2H). 
13C NMR (CDCl3, 126 MHz) δ 192.4, 159.8, 138.5, 137.9, 130.1, 123.5, 122.1, 115.0, 112.9, 
68.2, 33.5, 28.7, 25.4. 
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Calculated vs found mass difference table for the synthesized compounds with error in ppm 
SN 
Compound 
ID 
Molecular Formula 
Calculated 
Mass 
Found 
Mass 
Error 
(ppm) 
1 1.23.3a C11H15NO4SNa (M+Na) 280.0620 280.0627 2.5 
2 1.23.3b C11H14N2O6SNa (M+Na) 325.0470 325.0478 2.5 
3 1.23.4a C18H20ClNO4SNa (M+Na) 404.0699 404.0704 1.2 
4 1.23.4b C18H19ClN2O6SNa (M+Na) 449.0550 449.0559 2.0 
5 1.23.4c C18H21NO4SNa (M+Na) 370.1089 370.1103 3.8 
6 1.23.4d C18H20N2O6SNa (M+Na) 415.0940 415.0945 1.2 
7 1.23.4e C18H20FNO4SNa (M+Na) 388.0995 388.1010 3.9 
8 1.23.4f C18H19FN2O6SNa (M+Na) 433.0846 433.0862 3.7 
9 1.23.5a C17H17ClNO3S (M+H) 350.0618 350.0624 1.7 
10 1.23.5b C17H16ClN2O5S (M+H) 395.0468 395.0475 1.8 
11 1.23.5c C17H17NO3SNa (M+Na) 338.0827 338.0844 5.0 
12 1.23.5d C17H16N2O5SNa (M+Na) 383.0698 383.0706 2.1 
13 1.23.5e C17H16FNO3SNa (M+Na) 356.0733 356.0739 1.7 
14 1.23.5f C17H16FN2O5S (M+H) 379.0764 379.0782 4.7 
15 1.24.1a C25H22ClNO4SNa (M+Na) 490.0856 490.0866 2.0 
16 1.24.1b C24H19ClFNO3SNa (M+Na) 478.0656 478.0638 3.8 
17 1.24.1c C24H20ClNO3SNa (M+Na) 460.0750 460.0762 2.6 
18 1.24.1d C24H18ClFN2O5SNa (M+Na) 523.0607 523.0631 4.6 
19 1.24.1e C25H20ClN2O7S (M+H) 527.0680 527.0696 3.0 
20 1.24.1f C25H23NO4SNa (M+Na) 456.1245 456.1249 0.9 
21 1.24.1g C24H20FNO3SNa (M+Na) 444.1045 444.1053 1.8 
22 1.24.1h C25H22N2O6SNa (M+Na) 501.1096 501.1096 0.0 
23 1.24.1i C24H19FN2O5SNa (M+Na) 489.0996 489.0972 4.9 
24 1.24.1j C25H20N2O7SNa (M+Na) 515.0889 515.0878 2.1 
25 1.24.1k C26H21FN2O5SNa (M+Na) 515.1053 515.1039 2.7 
26 1.24.1l C25H22FNO4SNa (M+Na) 474.1146 474.1161 3.2 
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SN 
Compound 
ID 
Molecular Formula 
Calculated 
Mass 
Found 
Mass 
Error 
(ppm) 
27 1.24.1m C24H19F2NO3SNa (M+Na) 462.0946 462.0925 4.5 
28 1.24.1n C25H20FNO5SNa (M+Na) 488.0944 488.0928 3.3 
29 1.24.1o C26H21F2NO3SNa (M+Na) 488.1102 488.1097 1.0 
30 1.24.1p C25H21FN2O6SNa (M+Na) 519.1002 519.1017 2.9 
31 1.24.1q C25H19FN2O7SNa (M+Na) 533.0795 533.0810 2.8 
32 1.24.1r C26H20F2N2O5SNa (M+Na) 533.0959 533.0951 1.5 
33 2.7.3 C16H28NO3Si (M+H) 310.1838 310.1851 4.2 
34 2.10.2 C10H24NO3Si (M+H) 234.1525 234.1535 4.3 
35 2.7.4 C17H29NO5SSiNa (M+Na) 410.1433 410.1443 2.4 
36 2.10.3 C11H25NO5SSiNa (M+Na) 334.1120 334.1128 2.4 
37 2.8.1a C24H34ClNO5SSiNa (M+Na) 534.1508 534.1532 4.5 
38 2.8.1b C24H35NO5SSiNa (M+Na) 500.1903 500.1893 2.0 
39 2.8.1c C24H34FNO5SSiNa (M+Na) 518.1809 518.1820 2.1 
40 2.10.4a C18H30ClNO5SSiNa (M+Na)  458.1200 458.1194 1.3 
41 2.10.4b C18H31NO5SSiNa (M+Na) 424.1590 424.1585 1.2 
42 2.10.4c C18H30FNO5SSiNa (M+Na) 442.1496 442.1498 0.5 
43 2.9.1a C18H20ClNO5SNa (M+Na) 420.0648 420.0660 2.9 
44 2.9.1b C18H21NO5SNa (M+Na) 386.1033 386.1049 4.1 
45 2.9.1c C18H20FNO5SNa (M+Na) 404.0938 404.0948 2.5 
46 2.9.2a C21H24ClNO5SNa (M+Na) 460.0956 460.0970 3.0 
47 2.9.2b C21H25NO5SNa (M+Na) 426.1351 426.1353 0.5 
48 2.9.2c C21H24NO5SNa (M+Na) 444.1257 444.1277 4.5 
49 2.9.3a C20H20ClNO4SNa (M+Na) 428.0700 428.0718 4.2 
50 2.9.3b C20H21NO4SNa (M+Na) 394.1089 394.1095 1.5 
51 2.9.3c C20H20FNO4SNa (M+Na) 412.0995 412.1014 4.6 
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Methyl (methylsulfonyl)-L-phenylalaninate (1.22.3a) 
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Methyl (S)-2-(methylsulfonamido)-3-(4-nitrophenyl)propanoate (1.22.3b) 
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Methyl N-(4-chlorobenzyl)-N-(methylsulfonyl)-L-phenylalaninate (1.22.4a) 
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Methyl (S)-2-(N-(4-chlorobenzyl)methylsulfonamido)-3-(4-nitrophenyl)propanoate 
(1.22.4b) 
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Methyl N-benzyl-N-methylsulfonyl-L-phenylalaninate (1.22.4c) 
 
 
143 
 
Methyl (S)-2-(N-benzylmethylsulfonamido)-3-(4-nitrophenyl)propanoate (1.22.4d) 
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Methyl N-(4-fluorobenzyl)-N-(methylsulfonyl)-L-phenylalaninate (1.22.4e) 
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Methyl (S)-2-(N-(4-fluorobenzyl)methylsulfonamido)-3-(4-nitrophenyl)propanoate 
(1.22.4f) 
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 (S)-3-benzyl-2-(4-chlorobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5a) 
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 (S)-2-(4-chlorobenzyl)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5b) 
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 (S)-2,3-dibenzylisothiazolidin-4-one 1,1-dioxide (1.22.5c) 
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 (S)-2-benzyl-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5d) 
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 (S)-3-benzyl-2-(4-fluorobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5e) 
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 (S)-2-(4-fluorobenzyl)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide (1.22.5f) 
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 (S,E)-3-benzyl-2-(4-chlorobenzyl)-5-(4-methoxybenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1a) 
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 (S,E)-3-benzyl-2-(4-chlorobenzyl)-5-(4-fluorobenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1b) 
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 (S,E)-3-benzyl-5-benzylidene-2-(4-chlorobenzyl)isothiazolidin-4-one 1,1-dioxide 
(1.27.1c) 
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 (S,E)-2-(4-chlorobenzyl)-5-(4-fluorobenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 
1,1-dioxide (1.27.1d) 
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 (S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-2-(4-chlorobenzyl)-3-(4-nitrobenzyl) 
isothiazolidin-4-one 1,1-dioxide (1.27.1e) 
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 (S,E)-2,3-dibenzyl-5-(4-methoxybenzylidene)isothiazolidin-4-one 1,1-dioxide (1.27.1f) 
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 (S,E)-2,3-dibenzyl-5-(4-fluorobenzylidene)isothiazolidin-4-one 1,1-dioxide (1.27.1g) 
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 (S,E)-2-benzyl-5-(4-methoxybenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-
dioxide (1.27.1h) 
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(S,E)-2-benzyl-5-(4-fluorobenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 1,1-dioxide 
(1.27.1i) 
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 (S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-2-benzyl-3-(4-nitrobenzyl)isothiazolidin-4-
one 1,1-dioxide (1.27.1j) 
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(S,E)-2-benzyl-5-((E)-3-(4-fluorophenyl)allylidene)-3-(4-nitrobenzyl)isothiazolidin-4-one 
1,1-dioxide (1.27.1k) 
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 (S,E)-3-benzyl-2-(4-fluorobenzyl)-5-(4-methoxybenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1l) 
 
 
164 
 
 (S,E)-3-benzyl-2-(4-fluorobenzyl)-5-(4-fluorobenzylidene)isothiazolidin-4-one 1,1-
dioxide (1.27.1m) 
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 (S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-3-benzyl-2-(4-fluorobenzyl)isothiazolidin-
4-one 1,1-dioxide (1.27.1n) 
 
 
166 
 
 (S,E)-3-benzyl-2-(4-fluorobenzyl)-5-((E)-3-(4-fluorophenyl)allylidene)isothiazolidin-4-
one 1,1-dioxide (1.27.1o) 
 
 
167 
 
 (S,E)-2-(4-fluorobenzyl)-5-(4-methoxybenzylidene)-3-(4-nitrobenzyl)isothiazolidin-4-
one 1,1-dioxide (1.27.1p) 
 
 
168 
 
 (S,E)-5-(benzo[d][1,3]dioxol-4-ylmethylene)-2-(4-fluorobenzyl)-3-(4-nitrobenzyl) 
isothiazolidin-4-one 1,1-dioxide (1.27.1q) 
 
 
169 
 
 (S,E)-2-(4-fluorobenzyl)-5-((E)-3-(4-fluorophenyl)allylidene)-3-(4-nitrobenzyl) 
isothiazolidin-4-one 1,1-dioxide (1.27.1r) 
 
 
170 
 
Methyl (S)-2-amino-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propanoate (2.7.3) 
 
 
171 
 
Methyl O-(tert-butyldimethylsilyl)-L-serinate (2.10.2) 
 
 
172 
 
Methyl (S)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(methylsulfonamido)propanoate 
(2.7.4) 
 
 
173 
 
Methyl O-(tert-butyldimethylsilyl)-N-(methylsulfonyl)-L-serinate (2.10.3) 
 
 
174 
 
Methyl (S)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(N-(2-chlorobenzyl)methyl 
sulfonamido)propanoate (2.8.1a) 
 
 
175 
 
Methyl (S)-2-(N-benzylmethylsulfonamido)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl) 
propanoate (2.8.1b) 
 
 
176 
 
Methyl (S)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(N-(4-fluorobenzyl)methyl 
sulfonamido)propanoate (2.8.1c) 
 
 
177 
 
Methyl O-(tert-butyldimethylsilyl)-N-(2-chlorobenzyl)-N-(methylsulfonyl)-L-serinate 
(2.10.4a) 
 
 
178 
 
Methyl N-benzyl-O-(tert-butyldimethylsilyl)-N-(methylsulfonyl)-L-serinate (2.10.4b) 
 
 
179 
 
Methyl O-(tert-butyldimethylsilyl)-N-(4-fluorobenzyl)-N-(methylsulfonyl)-L-serinate 
(2.10.4c) 
 
 
180 
 
Methyl N-(2-chlorobenzyl)-N-(methylsulfonyl)-L-tyrosinate (2.9.1a) 
 
 
181 
 
Methyl N-benzyl-N-(methylsulfonyl)-L-tyrosinate (2.9.1b) 
 
 
182 
 
Methyl N-(4-fluorobenzyl)-N-(methylsulfonyl)-L-tyrosinate (2.9.1c) 
 
 
183 
 
Methyl (S)-3-(4-(allyloxy)phenyl)-2-(N-(2-chlorobenzyl)methylsulfonamido)propanoate 
(2.9.2a) 
 
 
184 
 
Methyl (S)-3-(4-(allyloxy)phenyl)-2-(N-benzylmethylsulfonamido)propanoate (2.9.2b) 
 
 
185 
 
Methyl (S)-3-(4-(allyloxy)phenyl)-2-(N-(4-fluorobenzyl)methylsulfonamido)propanoate 
(2.9.2c) 
 
 
186 
 
(S)-3-(4-(allyloxy)benzyl)-2-(2-chlorobenzyl)isothiazolidin-4-one 1,1-dioxide (2.9.3a) 
 
 
187 
 
 (S)-3-(4-(allyloxy)benzyl)-2-benzylisothiazolidin-4-one 1,1-dioxide (2.9.3b) 
 
 
188 
 
(S)-3-(4-(allyloxy)benzyl)-2-(4-fluorobenzyl)isothiazolidin-4-one 1,1-dioxide (2.9.3c)  
 
 
189 
 
3-(but-3-en-1-yloxy)benzaldehyde (2.11.5) 
 
 
190 
 
3-(pent-4-en-1-yloxy)benzaldehyde (2.11.4) 
 
 
191 
 
3-(hex-5-en-1-yloxy)benzaldehyde (2.11.6) 
 
 
192 
 
Crystal Structure for  
C25H22N2O6S 
Compound 1.27.1h 
 
 
193 
 
Crystal Structure for  
C25H21FN2O6S 
Compound 1.27.1p 
 
 
 
 
 
 
 
